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1. SUMMARY 
Carnitine is an endogenous amino acid derivative which plays a key role in energy 
metabolism. Through acylation of its -hydroxy group, carnitine is involved in the 
interorganellar transport of long-chain fatty acids and in the regulation of the coenzyme A 
pool. Carnitine is present in most mammalian tissues in its free form or as acylcarnitines of 
several chain lengths. 
The present work consists of three projects investigating analytical and physiological 
aspects of carnitine and its derivatives and emphasizing the essential function of carnitine 
in detoxifying processes and energy balance. 
The interest of the first project is the carnitine homeostasis in patients treated with the 
antiepileptic drug valproate. Although generally well tolerated, valproate is associated with 
carnitine deficiency through an unknown mechanism. We studied the effects of valproate on 
the carnitine balance in long term patients and in one patient starting a treatment with 
valproate, as well as in an in vitro model of the renal transport of carnitine by OCTN2. 
We show that a patient starting valproate treatment has decreased carnitine plasma 
concentrations in the initial phase of the therapy. After long term treatment, plasma 
concentrations of carnitine and acylcarnitines are similar to control patients, with the 
exception of valproylcarnitine which is only present in treated patients. Urinary excretions of 
carnitine are substantially lower in valproate patients, suggesting a renal compensatory 
mechanism. We pointed out that valproylcarnitine although not reabsorbed, barely 
contributes to the carnitine loss at the beginning of a therapy. 
The focus of the second project is the optimization of a LC-MS/MS method for the 
simultaneous determination of carnitine and acylcarnitines in plasma. For a rapid sample 
workup, we integrated an online solid phase extraction step to the chromatographic run 
after protein precipitation. Quantification was achieved with the addition method to account 
for matrix effects. We report a reliable method for the quantification of carnitine, 
acetylcarnitine, octanoylcarnitine, and palmitoylcarnitine requiring minimal sample workup, 
short analysis time and low sample volumes. 
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In the last project we investigated the effects of carnitine, acetylcarnitine and 
propionylcarnitine on the carnitine muscle balance and on the performance of mice 
completing a running exercise until exhaustion. Carnitine and its two acyl-derivatives did not 
influence the total muscle carnitine content or the physical performance. Accordingly, we 
did not observe significant differences of muscular respiration or energy parameters such 
as lactate, glycogen or phosphocreatine between treated and control groups. 
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2. ABBREVIATIONS 
ACN  Acetyl-L-carnitine 
ADAM 9-anthryldiazomethane 
ATP  Adenosine-5’-triphosphate 
-BB  -Butyrobetaine 
Br-DMEQ 3-bromomethyl-6,7-dimethoxy-1-methyl-2-quinoxalinone 
BSA  Bovine serum albumin 
CACT  Carnitine-acylcarnitine translocase 
CAT  Carnitine acetyltransferase 
CE  Capillary electrophoresis 
CN  L-Carnitine 
CoA  Coenzyme A 
CoASH Free Coenzyme A 
COT  Carnitine octanoyltransferase 
CPT  Carnitine palmitoyltransferase 
DBS  Dried blood spot 
DTNB  5,5’-dithiobis-2-nitrobenzoic acid 
EDAC  1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ESI  Electrospray ionization 
FAB  Fast atom bombardment 
FAD  Flavin adenine dinucleotide 
FADH2 Flavin adenine dinucleotide reduced form 
FDA  Food and Drug Administration 
FMN  Flavin mononucleotide 
GC  Gas chromatography 
HPLC  High performance liquid chromatography 
HTML  3-hydroxy-trimethyl lysine 
IMM  Inner mitochondrial membrane 
JVS  Juvenile visceral steatosis 
MCAD Medium-chain acylcarnitine dehydrogenase 
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MCD  Muscular carnitine deficiency 
MS  Mass spectrometry 
NADH  Nicotinamide adenine dinucleotide 
NBD-ED 4-(2-aminoethylamino)-7-nitro-2,1,3-benzoxadiazole 
OAT  Organic anion transporter 
OCTN  Organic cation/carnitine novel transporter 
OMM  Outer mitochondrial membrane 
PCN  Propionylcarnitine 
PDC  Pyruvate dehydrogenase complex 
PPAR Peroxisome proliferator-activated receptor alpha 
REA  Radioenzymatic assay 
RIE  Radio isotopic exchange 
SCD  Systemic carnitine deficiency 
SDH  Succinate dehydrogenase 
THP  Trimethyl hydrazinium propionate 
TMABA 4-trimethylaminobutyraldehyde 
TML  Trimethyllysine 
UV  Ultra violet 
VDAC  Voltage dependent anion channel 
VPA  Valproic acid 
VO2 max Maximal aerobic capacity 
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3. INTRODUCTION 
3.1. General aspects 
Carnitine is a small water soluble molecule that owes its name to the Latin word caro, 
carnis meaning flesh. It was discovered in muscle tissue by two independent groups in the 
same year: Gulewitsch and Krimberg (Gulewitsch et al., 1905) who gave carnitine its actual 
name and Kutscher who named this new substance “novaine” (Kutscher, 1905), a name 
that was abandoned three years later (Krimberg, 1908). The structure of carnitine was 
elucidated in 1927 by Tomita and Sendju (Tomita et al., 1927). Carnitine is a zwitterionic 
molecule physiologically present as L-enantiomer (Figure 1). 
Because of its essential character for the survival of the meal worm Tenebrio molitor, 
carnitine was first thought to be a vitamin and was also called vitamin BT (Fraenkel, 1948). 
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Figure 1: Structure of L-carnitine (A) and acyl-L-carnitines (B) 
 
In the mid 1950s, the best known role of carnitine as fatty acyl carrier was brought to light 
by Fritz, who observed a stimulation of long-chain fatty acids oxidation with addition of 
carnitine (Fritz, 1955). Growing interest and growing research led to the discovery of other 
important roles of carnitine such as its acetyl-CoA/CoA buffering capacity or acyl groups 
detoxifying faculty (Bieber, 1988; Childress et al., 1967). 
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A 70-kg healthy man contains a pool of about 20 g of carnitine, principally located in the 
skeletal and heart muscles (Brass, 1995). In the body, carnitine can be found in its free or 
acylated form, so-called acylcarnitine (Figure 1). Depending on the chain length of the acyl 
group, the acylcarnitine is referred to as short chain (C1-C5), medium chain (C5-C11) or 
long chain acylcarnitine (> C12) (Roth, 2009). Very-long chain acylcarnitines have also 
been described (C >22), involved in peroxisomal trafficking (Duranti et al., 2008).  
Our main carnitine source is food such as meat or dairy products; about 25% of our body 
pool comes from biosynthesis. Endogenous carnitine is produced from the two amino acids 
methionine and lysine in a four-step enzymatic pathway (Figure 2). 
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Figure 2: Biosynthesis of L-carnitine (adapted from Vaz and Wanders, 2002) 
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The first building block in the biosynthesis of carnitine is trimethyllysine (TML), the 
methylation product of protein bound lysine with S-adenosylmethionine. TML is 
hydroxylated by TML dioxygenase to generate 3-hydroxy-TML (HTML). HTML is cleaved to 
4-trimethylaminobutyraldehyde (TMABA) and glycine by the enzyme HTML aldolase. The 
enzyme TMABA dehydrogenase catalyzes the dehydrogenation step of TMABA to 
-butyrobetaine (-BB). This molecule is hydroxylated at its 3-position by -BB dioxygenase, 
yielding carnitine. The enzymes of the carnitine biosynthesis pathway are ubiquitous except 
for the enzyme of the last step, mostly active in liver and kidney and to a lesser extent in the 
brain. Cofactors such as vitamin B6, vitamin C, -ketoglutarate or iron are needed for the 
biosynthesis of carnitine (Vaz et al., 2002b). 
3.2. Functions of carnitine 
3.2.1. Acyl-CoA trafficking 
3.2.1.1. Across the mitochondrial membranes 
The most well-known function of carnitine is its shuttling activity of long chain fatty acids 
from the cytosol to the mitochondrial matrix for -oxidation. This function came to light with 
the work of Fritz who observed enhanced oxygen consumption and labeled CO2 formation 
from marked palmitate in liver homogenates incubated with carnitine (Fritz, 1955). Long 
chain fatty acids, unlike short and medium chain fatty acids entering via diffusion, have to 
be coupled to carnitine to enter the mitochondrion (Bremer, 1983). 
The translocation of long chain fatty acids into the mitochondrion is a four-step process 
(Figure 3). First, fatty acids are activated to fatty acyl-CoA by the action of the enzyme 
acyl-CoA synthetase, also called acyl-CoA ligase, classified according to their chain length 
specificity (Groot et al., 1976). 
The long chain fatty acyl-CoAs are esterified to the -hydroxy group of carnitine, a reaction 
catalyzed by a protein of the outer mitochondrial membrane (OMM), carnitine-palmitoyl 
transferase 1 (CPT1). Three isoforms of CPT1 have been described: CPT1A, present in the 
liver and kidney mainly, CPT1B, in the skeletal and cardiac muscles, and CPT1C in the 
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brain. CPT1 is considered as the rate limiting step of -oxidation. The liver isoform is 
regulated by malonyl-CoA, an intermediate of fatty acid biogenesis (Bonnefont et al., 2004). 
It has been suggested recently that acyl-CoA synthetase, CPT1 and the voltage-dependent 
anion channel (VDAC) tightly interact, allowing the transfer of long-chain fatty acids through 
the OMM (Lee et al., 2011). 
The acylcarnitines produced by CPT1 cross the inner mitochondrial membrane via the 
protein carnitine-acylcarnitine translocase (CACT), embedded in the inner mitochondrial 
membrane (IMM). CPT2, also a protein of the IMM is responsible for the conversion of 
acylcarnitines back to carnitine and acyl-CoA, subsequently entering -oxidation. CPT2 is 
ubiquitous and present as one isoform (Bonnefont et al., 2004). 
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Figure 3: The carnitine-fatty acid shuttle (adapted from Vaz 2002) 
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3.2.1.2. From peroxisomes 
Carnitine also plays a role in the metabolic function of peroxisomes. These organelles are 
involved in the oxidation of several chemical entities such as very-long chain fatty acids or 
branched fatty acids. To some extent, peroxisomes also contribute to the -oxidation of 
long chain fatty acids (Steiber et al., 2004). In the mitochondria, fatty acids are completely 
oxidized to CO2; in peroxisomes, their oxidation yields acetyl-CoA, propionyl-CoA or chain 
shortened fatty acyl-CoA (Wanders et al., 2010). 
Fatty acids import into peroxisomes is not a carnitine dependent process as it is in 
mitochondria. First theories suggested the existence of an unspecific pore-forming protein 
in the peroxisomal membrane, through which fatty acids could freely diffuse (Van 
Veldhoven et al., 1987). Nowadays evidence supports the presence of a specific import 
system for activated fatty acids, involving ABC transporters (Theodoulou et al., 2006; Visser 
et al., 2007). 
While the import of fatty acids into the peroxisome has been shown to be carnitine 
independent, the export of shortened fatty acids requires the presence of carnitine. Jakobs 
and Wanders brought evidence that oxidation of the branched fatty acid pristanic acid 
needs the carnitine-acylcarnitine translocase to run to completion (Jakobs et al., 1995). 
Metabolomic studies on fibroblasts with known peroxisomal defects further indicated that 
the complete oxidation of branched fatty acids to CO2 requires all the enzymes of the 
carnitine shuttle but CPT1 (Verhoeven et al., 1998). 
Together with the fact that peroxisomes contain carnitine acetyl-transferase (CAT) and 
carnitine octanoyl-transferase (COT), this indicates that shortened fatty acid are converted 
to carnitine esters in the peroxisomes. Carnitine esters are then exported from the 
peroxisomes to the cytosol and finally translocated in the mitochondrion via CACT, where 
they are oxidized to CO2 (Jakobs et al., 1995). The transporter responsible for the export of 
acylcarnitines was suggested to be OCTN3 (Lamhonwah et al., 2005). 
3.2.1.3. Other compartments 
Specific studies of acylcarnitines profiles and localization of carnitine acyltransferases 
extended the list of carnitine’s functions beyond the well-known translocation of fatty acids 
into the mitochondria. 
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In erythrocytes, carnitine plays a role in the phospholipids turnover, explaining the presence 
of CPT1 in these cells devoid of mitochondria (Arduini et al., 1992). Acylcarnitines serve as 
reserve of acyl-groups for the renewal of phospholipids, ensuring membrane integrity of 
erythrocytes. 
In neurons, carnitine has been suggested to be an intermediate of the synthesis of 
ceramide and sphingolipids, via the action of the microsomal CPT1c (Sierra et al., 2008). 
Evidence supports a role of carnitine in the transfer of acetyl groups from the mitochondria 
to the nucleus for histone acetylation, justifying CAT activity in the nuclear compartment 
(Madiraju et al., 2009). 
3.2.2. CoA homeostasis 
3.2.2.1. Acetyl-CoA buffering 
Acetyl-CoA is an intermediate at the crossways of many metabolic pathways with regulatory 
influence on key enzymes such as the pyruvate dehydrogenase complex (PDC) 
(Constantin-Teodosiu et al., 1991). To avoid a misbalance of the acetyl-CoA to CoA ratio, 
the enzyme carnitine acetyltransferase (CAT) conjugates acetyl-CoA to carnitine, 
generating acetylcarnitine. In conditions enhancing acetyl-CoA formation, such as 
exhaustive exercise, acetylcarnitine concentrations increase (Friolet et al., 1994). 
3.2.2.2. Acyl detoxifier 
Carnitine buffering capacity is not limited to acetyl-CoA. Accumulating CoA derivatives, 
which are impermeable to membranes, are converted to their carnitine derivative for 
elimination. Several metabolic disorders or drug treatments have been associated with 
specific acylcarnitines patterns. For example in plasma of patients with medium-chain acyl-
CoA dehydrogenase deficiency, elevated octanoylcarnitine concentrations, as an 
expression of accumulating octanoyl-CoA, are noticeable (Van Hove et al., 1993). During 
treatment with pivalate prodrugs such as pivampicillin, pivaloylcarnitine is excreted (Melegh 
et al., 1987). Profiling of acylcarnitines as markers of metabolic disorders is widespread for 
many clinical applications.  
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3.2.3. Other functions of carnitine 
A multitude of other functions have been attributed to carnitine. Carnitine has been shown 
to be osmoprotective for certain bacteria or in organs such as the lens (Peluso et al., 2000). 
Carnitine has also been involved in the immune response in several models (Famularo et 
al., 2004; Fortin et al., 2009) or in the glucose homeostasis and insulin sensitivity (Ringseis 
et al., 2012). Hormon-like activity has been associated to carnitine, as allosteric regulator of 
glucocorticoid receptor (Alesci et al., 2003) or as peripheral antagonist of thyroid hormones 
(Benvenga et al., 2004) for example. Also antioxidative properties are conferred to carnitine 
(Cao et al., 2011). 
3.3. Carnitine homeostasis 
Carnitine balance is a tightly regulated process involving biosynthesis, intestinal absorption, 
renal reabsorption and tissue distribution. An important concentration gradient between 
plasma and skeletal muscle where no carnitine synthesis takes place and efficient renal 
reabsorption of more than 90% of the filtered carnitine implicate an active transporter. The 
main and most investigated carnitine transporter is the novel organic cation transporter 2 
OCTN2 (SLC22A5) cloned in 1998 (Tamai et al., 1998). OCTN2 is a multi-specific cation 
transporter taking up carnitine with an affinity in the low micromolar range (Berardi et al., 
2000; Tamai et al., 1998). Unlike other substrates of OCTN2, carnitine is transported in a 
sodium dependent way in a 1:1 stoichiometry (Ohashi et al., 1999; Stieger et al., 1995). 
OCTN2 is present in various tissues: it is expressed in kidney, heart, skeletal muscle, 
intestine, placenta, testis, and brain among other organs (Tamai et al., 1998). 
Compromised uptake of carnitine in fibroblasts, myocytes, liver or renal tubule of OCTN2-
deficient mice or patients illustrates the central role of OCTN2 for carnitine homeostasis 
(Pons et al., 1997; Yokogawa et al., 1999). 
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Carnitine is also transported by other members of the SLC22 family: OCTN1, OCTN3, and 
OCT6 (CT2) are polyspecific carnitine/organic cations transporters (Koepsell et al., 2007). 
These transporters differ in their mode of transport and in their affinity to carnitine. OCTN1 
is a proton/cation exchanger. Whereas OCTN2 mediates carnitine transport is a 
Na+ dependent manner, OCTN3 and OCT6 showed no sodium-dependency. All of these 
transporters except OCTN1 carry carnitine with high affinity. In mouse, the anion 
transporter Oat9 has been reported to transport carnitine with high affinity in liver and 
kidney (Tsuchida et al., 2010). The multi-component transport reported in many organs 
(Kato et al., 2006; Stieger et al., 1995; Yokogawa et al., 1999) relies probably on the 
presence of OCTN2, other transporters and passive diffusion. 
The absorption of carnitine depends on the dietary intake. In function of the diet, whether 
strict vegetarian or omnivorous, an individual can ingest between 0.05-15 mol/kg of 
carnitine per day (Rebouche et al., 1993). The main site of carnitine absorption is the small 
intestine (Matsuda et al., 1998). Bioavailability of dietary carnitine exceeds 50% whereas 
the bioavailability of supplemented carnitine is about 15% (Rebouche, 2004). 
The part not taken up is degraded mainly to trimethylamine and butyrobetaine by the 
intestinal flora. Parenteral carnitine is found almost exclusively unchanged in urine, 
indicating that no metabolism takes place in humans (Rebouche et al., 1991). 
Daily rate of carnitine biosynthesis has been estimated at 1.2 mol/kg, taking place 
essentially in the liver (Vaz et al., 2002b). 
The renal filtration clearance of the small and polar carnitine is close to the glomerular 
filtration rate (100-120 mL/min). In a normal situation though, carnitine is almost completely 
reabsorbed, mainly by the action of OCTN2 in the apical membrane of the proximal tubule 
(Tamai et al., 2001). In healthy adults, the renal carnitine clearance is in the range 
1-3 mL/min with a renal threshold of about 50 M (Evans et al., 2003). 
Kidney adapts to the dietary intake or more precisely to the circulating carnitine to ensure 
an optimal balance of the carnitine pool (Rebouche et al., 1993; Schurch et al., 2010). 
Individuals on a strict vegetarian diet typically have lower carnitine clearance to 
compensate for their low dietary intake (Lombard et al., 1989). 
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Carnitine homeostasis is tightly regulated. In mice, expression of OCTN2 has been shown 
to be enhanced by PPAR activation as is the expression of enzymes of carnitine 
biosynthesis (Ringseis et al., 2009; Wen et al., 2011). Hormonal influence has also been 
established (Genuth et al., 1981; Stephens et al., 2007b). 
3.4. Carnitine deficiency 
Deficient carnitine levels can lead to an accumulation of long chain fatty acids or potentially 
toxic acyl-products, impairing the cellular function. Symptoms such as muscle weakness, 
fatigue, encephalopathy, cardiomyopathy, and hypoketotic hypoglycaemia are associated 
with carnitine deficiency. Low carnitine levels can be primary as inherited carnitine 
transporter defect, or secondary as a result of an excessive loss or a diminished supply of 
carnitine. While decreased plasma or tissue concentrations of carnitine can be observed in 
many clinical situations, symptomatic carnitine deficiencies are rather uncommon. 
Symptoms are believed to appear at very low concentrations of carnitine only (<10% of 
normal) (Stanley, 2004), in accordance with the fact that individuals with primary carnitine 
deficiency can remain undetected although their carnitine plasma levels are almost non-
existent (El-Hattab et al., 2010; Spiekerkoetter et al., 2003). 
3.4.1. Primary deficiency 
Two forms of primary carnitine deficiencies have been distinguished, muscular carnitine 
deficiency (MCD – OMIM 212160) and systemic carnitine deficiency (SCD – OMIM 
212140). 
First described in 1973 (Engel et al., 1973), MCD is characterized by low carnitine levels in 
skeletal muscle associated with muscle weakness and lipid storage myopathy, affecting 
mostly type I fibers. Onset of myopathy occurs generally during early adulthood. Symptoms 
can range from mild myalgia to fatal outcome. Since carnitine plasma concentrations are 
usually not altered, a deficiency in a low affinity muscular transporter has been suggested 
(Martinuzzi et al., 1991). Some patients with MCD benefit from a carnitine supplementation 
while others do not. Corticosteroid therapy improved symptomatology in some cases 
(Vielhaber et al., 2004). 
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The first case of systemic carnitine deficiency was reported in 1975 (Karpati et al., 1975). 
Symptoms of SCD, usually appearing during early childhood, are multiple. Muscle 
weakness, progredient cardiomyopathy, lethargy, hypoketotic hypoglycemia, vomiting, 
seizures, fatigue, and failure to thrive can be clinical signs of systemic carnitine deficiency. 
Not only carnitine concentrations in muscle are reduced but also in other organs such as 
the liver. Systemic carnitine deficiency is an autosomal recessive disorder due to a genetic 
mutation of the SLC22A5 gene encoding OCTN2 (Nezu et al., 1999). Many point mutations 
have been described with varying phenotypes (Rose et al., 2011). 
First described in 1988, the juvenile visceral steatosis (jvs) mouse is a model of systemic 
carnitine deficiency. Characterized by retarded growth and hepatic microvesicular 
infiltrations, jvs mice have a mutation of the OCTN2 gene, resulting in an impaired carnitine 
transport (Koizumi et al., 1988; Kuwajima et al., 1991). 
3.4.2. Secondary deficiency 
Secondary carnitine deficiencies have several etiologies. They can be due to increased 
carnitine loss or impaired supply of genetic, physiological or iatrogenic origin. 
3.4.2.1. Genetic origin 
Several metabolic disorders such as fatty acid oxidation disorders or organic acidurias are 
associated with an increased urinary loss of carnitine. Accumulating fatty acids or organic 
acids are converted to their carnitine derivatives for elimination. In the kidney, acylcarnitines 
are reabsorbed with much lower affinity than carnitine itself, causing a depletion in the 
carnitine pool (Ohnishi et al., 2008). For example, in plasma and urine samples of patients 
with medium chain acyl-CoA dehydrogenase deficiency (MCAD), increased medium chain 
acylcarnitine such as octanoylcarnitine are observed in consequence of the accumulating 
activated esters. In these patients, plasmatic octanoylcarnitine concentrations can be 
100 times higher than normal (Chace et al., 1997). Another example is methylmalonic 
aciduria, as result of a defective methylmalonyl-CoA mutase, characterized by elevated 
propionyl- and methylmalonylcarnitine levels, enhancing a renal loss of carnitine (Chalmers 
et al., 1984). 
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Mutations of the enzymes of the carnitine shuttle have also been described, leading to more 
or less severe phenotypes not necessarily accompanied by insufficient carnitine 
concentrations (Bonnefont et al., 2004; Stanley et al., 1992). 
3.4.2.2. Iatrogenic carnitine deficiencies 
Hemodialysis 
Patients with chronic renal failure have an impaired carnitine homeostasis, characterized by 
reduced free carnitine concentrations and elevated acylcarnitines to carnitine ratio in 
plasma (Vernez et al., 2006). During dialysis, small and hydrophilic compounds such as 
carnitine or its metabolic precursor butyrobetaine are filtered out, contributing to a loss of 
carnitine via filtration and reduced biosynthesis. Patients with hemodialysis can profit from 
carnitine supplementation for muscular, cardiac or anemic symptoms but no general 
consensus exist because of the lack of large-scale clinical studies (Calo 2012). 
Drug induced 
Several drugs are associated with impaired carnitine homeostasis. While some of them 
directly interact with the carnitine transporter or the carnitine biosynthesis pathway, others 
induce a carnitine loss via formation of unabsorbable carnitine derivatives. 
Valproate (VPA) is a branched fatty acid used as antiepileptic, mood stabilizer or migraine 
prophylaxis. VPA is usually well tolerated but has been associated with hepatic failure 
and/or carnitine deficiency. More than ten metabolites of VPA have been described, one of 
them being valproylcarnitine (Peterson et al., 2005). 
Many studies have reported changes in carnitine and/or acylcarnitines levels in patients 
taking valproate in monotherapy or polytherapy. Some authors observed a decrease in total 
and free carnitine in plasma samples of VPA patients (Chung et al., 1997; Rodriguez-
Segade et al., 1989) while others did not (Silva et al., 2001). The age of the patients 
seemed to be linked to decreased plasma carnitine levels, children less than 10 years of 
age being more sensitive. 
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In two studies (Silva et al., 2001; Werner et al., 2007), the fate of C8 acylcarnitines 
(octanoylcarnitine and valproylcarnitine) was investigated. Werner and colleagues observed 
a slight increase of the C8 species with valproate treatment while Silva and coworkers did 
not report any differences. 
To explain the carnitine deficiency associated with VPA, several modes of action have been 
suggested (Tein et al., 1993): inhibition of carnitine uptake by valproylcarnitine or another 
VPA metabolite, interference of metabolites such as 4-ene-valproate with -oxidation or 
other energetic pathways were brought into question. The direct inhibitory effect of valproic 
acid on OCTN2 was studied by Wagner et al. (Wagner et al., 2000), but it showed no 
significant results, which presumes another mechanism. Okamura and colleagues 
(Okamura et al., 2006) investigated the effect of valproylcarnitine on OCTN2 and concluded 
on a non-competitive inhibition with a Ki of 41.6 M. 
Mildronate (trimethyl hydrazinium propionate, THP) is a carnitine analogon that has been 
used as cardioprotective agent. THP induces a carnitine deficiency through inhibition of 
OCTN2 and -butyrobetaine dioxygenase, the last enzyme of the carnitine biosynthesis 
pathway. This substance has been used to generate a carnitine deficiency in a rat model 
(Spaniol et al., 2001). 
Pivalic acid has been used to enhance the bioavailability of several drugs such as the 
antibiotic ampicillin. Rapidly hydrolyzed from the active part, the pivaloyl moiety is 
converted to pivaloyl-CoA. The non-metabolized CoA derivative is conjugated to carnitine 
for elimination (Brass, 2002). Pivaloylcarnitine was shown to inhibit the OCTN2-dependent 
renal reabsorption of carnitine in a competitive manner. The renal loss of carnitine in the 
form of the weakly reabsorbed pivaloylcarnitine rather than the uptake inhibition underlies 
the carnitine deficiency observed with pivalate prodrugs treatment (Todesco et al., 2009). 
Other direct inhibitors of OCTN2 have been described (Ohashi et al., 1999; Wu et al., 
1999). Some inhibitors structurally unrelated to carnitine such as emetine or zidovudine 
(Wu et al., 1999) have been associated with clinical manifestations of carnitine deficiency 
(Dalakas et al., 1994; Kuntzer et al., 1990). Modulators of OCTN2 expression such as 
antineoplastic platinum-derivatives have also been described (Haschke et al., 2010). 
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3.4.2.3. Physiological carnitine deficiency 
The carnitine pool of an omnivorous individual comes mostly from the diet. Decreased 
intake of carnitine can be observed in patients with parenteral nutrition (Nanni et al., 1983), 
malabsorption disorder such as celiac disease (Lerner et al., 1993), or vegetarian diet 
(Lombard et al., 1989). Low intake alone is rarely associated with carnitine deficiency, but 
concomitant pathological states can favor a carnitine deficiency (Wennberg et al., 1992). 
Liver is central for the biosynthesis and turnover of carnitine. Depending on the etiology of 
the liver disease, increased or decreased carnitine plasma concentrations have been 
observed (Krähenbühl, 1996). 
During pregnancy, plasma carnitine concentrations drop to 50% of the initial concentration 
(Cederblad et al., 1986). Asymptomatic in most cases, the carnitine decrease can be critical 
with an underlying disease (Angelini et al., 1978; Cederblad et al., 1986; Donnelly et al., 
2007). Other high energy demanding states such as severe burns (Cederblad et al., 1980) 
or sepsis (Eaton et al., 2005) are also associated with disturbed plasmatic and urinary 
carnitine concentrations, reflecting increased demand or muscle wasting. 
3.5. Analysis of carnitine and acylcarnitines 
3.5.1. Early approaches 
The first quantitative approach for the determination of carnitine was reported in 1954 
(Fraenkel, 1954). The assay was based on the essential character of carnitine for the 
growth of the larvae of Tenebrio molitor. After hatching, the worms can grow and survive for 
3-4 weeks in the absence of carnitine; after this period, survival is compromised. Knowing 
the amount of carnitine needed for an optimal survival and a suboptimal growth rate, the 
concentration of carnitine in a testing material could be assessed. Although the Tenebrio 
test showed quite reproducible results according to its authors, it was limited in terms of 
precision, specificity and time efficiency.  
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The Tenebrio molitor assay was supplanted by colorimetric methods such as the one 
developed by Friedman (Friedman, 1958). Bromophenol blue was added to purified 
extracts of meat or urine containing carnitine, leading to the formation of a carnitine ester of 
bromophenol. The colorimetric determination of the ester allowed a quantification of 
carnitine in the low micromolar range (0.03-0.19 mol). Because of the reactivity of 
quaternary ammonium groups with bromophenol, this method requires pure extracts to 
ensure selectivity. 
3.5.2. Enzymatic assays 
A major progress for the analysis of carnitine was achieved in 1964: Marquis & Fritz 
developed an enzymatic assay (Marquis et al., 1964) relying on the reaction catalyzed by 
the enzyme carnitine acetyltransferase (CAT) (1). In the first version of this enzymatic 
assay, the product of the CAT reaction was determined spectrophotometrically. Following 
reactions are involved in the assay: 
 
(1)   Acetyl-CoA + Carnitine  Acetylcarnitine + CoASH 
 
(2)      
NO2
COO-S
NO2
COO-HS
S
CoA
NO2
COO-S
S
O2N
-OOC
CoASH +
+
 
 
In the presence of a compound with a sulfhydryl group such as CoASH, DTNB is cleaved 
into two 5-thio-2-nitrobenzoate moieties. One of the benzoates reacts with the sulfhydryl 
group while the other remains free (2). This free part is yellow and its absorbance can be 
determined at 412 nm. With constant levels of substrates, the carnitine present in the 
biological sample will generate an equimolar amount of CoASH and subsequently of the 
free thionitrobenzoate. 
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Any sulfhydryl group can cleave DTNB, generating a signal independent of the CoASH 
formed by CAT. To avoid this interference, SH groups were oxidized while the tissue 
extracts were heated at 90°C for 5 minutes at pH 8.5. The assay of Marquis and Fritz could 
detect carnitine amounts as low as 5 nmol in rat tissues such as liver, brain, muscle or 
serum. 
Cederblad and Lindstedt published a method for the measurement of carnitine in the 
picomole range, relying as well on the carnitine acetyltransferase reaction (Cederblad et al., 
1972). This assay is the first so-called REA – radio enzymatic assay – for the determination 
of carnitine, based on the use of radioactive labeled acetyl-CoA as CAT substrate. 
Perchloric acid extracts of plasma and muscle samples were incubated with 14C-acetyl-CoA 
and CAT, and then purified on an anion exchange column to remove unreacted acetyl-CoA. 
The generated 14C-acetylcarnitine was detected in a scintillation counter. The carnitine 
content of plasma and muscle extracts ranging from 20 to 2000 picomoles could be 
assessed. 
Since the enzyme CAT catalyzes an equilibrium reaction, endogenous acetylcarnitine can 
integrate a labeled acetyl group. Unless the reaction (1) is shifted to the acetylcarnitine 
side, both carnitine and acetylcarnitine will be detected as labeled acetylcarnitine and not all 
the carnitine present in the testing material will be converted to 14C-acetylcarnitine. If 14C-
acetyl-CoA and carnitine are present in similar concentrations, the response between 
carnitine and 14C-acetylcarnitine will not be in a linear range. This can be circumvented by a 
large excess of acetyl-CoA or by trapping the CoASH formed. Due to the high cost of 14C-
acetyl-CoA, the second alternative has been further developed. 
Bohmer and colleagues used DTNB, known to react with sulfhydryl groups, as CoASH 
scavenger (Bohmer et al., 1974). The problem was partially solved, since relative high 
amounts of acetyl-CoA were still needed and DTNB was found to be an inhibitor of the 
enzyme CAT. 
In another version of the radioenzymatic assay, DTNB has been replaced by the oxidizing 
agent sodium tetrathionate (McGarry et al., 1976). The method allows the determination of 
carnitine and total carnitine with good linearity and no interference with short-chain 
acylcarnitines. To optimize the time frame of the procedure, plasma without protein 
precipitation as well as anion exchange resin in solution were used. 
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Pace and colleagues adapted the method of McGarry to liver and muscle samples (Pace et 
al., 1978). Unlike plasma, those organs contain notable amounts of acetyl-CoA potentially 
interfering with the assay. To avoid cross reactivity, higher amounts of labeled acetyl-CoA 
were used. The samples were treated with perchloric acid, so that differentiation between 
carnitine, short chain- and long chain-acylcarnitines in function of the extract fraction was 
achieved. 
Another variation of the enzymatic assay based on the CAT reaction was published by 
Parvin and Pande. The CoASH trapping agent N-ethylmaleimide or oxidized glutathione 
was substituted to sodium tetrathionate. Instead of the anion exchange resin, charcoal was 
used to adsorb the unreacted labeled acetyl-CoA (Parvin et al., 1977). 
Carnitine determination with REA provides accurate results with a relatively good 
sensitivity. However, the assay is time consuming and not optimal for routine analysis. 
Besides, only a rough differentiation of acylcarnitines in chain length categories is possible, 
with no distinction of the individual acylcarnitines. 
Other enzymatic reactions have been exploited for the determination of carnitine. 
Matsumoto and colleagues used the enzyme carnitine dehydrogenase to convert carnitine 
into dehydrocarnitine with concomitant formation of NADH. This NADH was then processed 
by the enzyme diaphorase to transform resazurin into the fluorescent resorufin (Matsumoto 
et al., 1990). With a flow injection system and immobilized enzymes, this assay is quite 
rapid but like the CAT reaction, it has the disadvantage of assessing carnitine without 
differentiation of its esters. 
3.5.3. Chromatographic methods 
The major advantage of a chromatographic approach is the possibility to separate carnitine 
and acylcarnitines. Under appropriate conditions, any carnitine ester can theoretically be 
distinguished from the next related acylcarnitine. 
Various chromatographic techniques have been applied to the identification and 
quantification of carnitine and its derivatives. While thin layer chromatography (Wittels et al., 
1965) played a precursor role for the analysis of carnitine, gas chromatography (GC) and 
especially high performance liquid chromatography (HPLC) made a major contribution to 
the domain. 
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Analysis of carnitine and its esters with GC requires a few detours given the non-volatile 
nature and the thermal instability of the analytes. These non-ideal properties have been 
exploited in different manners. In a first GC approach, Lewin and colleagues took 
advantage of the thermal lability of carnitine and monitored its fragments after heat 
degradation (Lewin et al., 1975). Other authors determined acyl moieties after hydrolysis of 
the acylcarnitines (Bieber et al., 1977), with the disadvantage of losing the integrity of the 
acylcarnitines and potentially assessing acyl groups coming from other esters. Another way 
to get heat stable volatile compounds is by derivatization. Several methods have been 
reported: Lowes & Rose analyzed acylcarnitines in urine via conversion to acyl-containing 
lactones and detection with mass spectrometry (Lowes et al., 1990). Huang and colleagues 
also used GC-MS but with another derivatization procedure: acylcarnitines were first 
esterified with propyl chloroformate followed by on-column N-dealkylation mediated by 
potassium iodide (Huang et al., 1991). 
Liquid chromatography has been widely used for qualitative and quantitative purposes, with 
various detection methods such as UV (Bhuiyan et al., 1987; Minkler et al., 1990), 
fluorescence (Kamimori et al., 1994; Longo et al., 1996), radioactivity measurement 
(Hoppel et al., 1986; Kerner et al., 1983), or mass spectrometry (Vernez et al., 2004). Mass 
spectrometric methods, coupled or not to HPLC will be discussed in the next section. 
The simultaneous chromatographic separation of carnitine and its derivatives is a 
challenging task: the carnitine family covers a wide interval of lipophilicities, ranging from 
the small and polar carnitine up to protein bound long and very-long chain acylcarnitines 
(Marzo et al., 1991). Normal phase HPLC has been marginally used for the determination 
of carnitine (Yoshida et al., 1988), while reversed phase is the most popular option when 
analyzing both carnitine and its derivatives (Minkler et al., 1990; Takeyama et al., 1986; 
Vernez et al., 2003). To optimize the retention of carnitine and short-chain acylcarnitines, 
ion pairing reagents such as butanesulfonic acid (Kerner et al., 1983), heptafluorobutyric 
acid (Vernez et al., 2003) or IPCC-MS3 (Maeda et al., 2007) have been used. 
The first objective of chemical derivatization, besides ameliorating chromatographic 
properties, is to couple a chromophore to carnitine and acylcarnitines for ultraviolet or 
fluorescence detection. Carnitine and its derivatives are only weakly detected in the UV 
range with poor sensibility and sensitivity (Hoppel et al., 1986). Several derivatization 
agents have been used for both UV and fluorescence detection. 
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One of the first HPLC-UV methods is based on the reaction of the carboxyl group of 
carnitine with 4’-bromophenacyl trifluoromethylsulfonate, yielding the 4’-
bromophenacylester absorbing at 254 nm (Minkler et al., 1990). The reaction can occur 
under mild conditions and is completed within 10 minutes. Other derivatizing agents such 
as p-bromophenacyl bromide (Poorthuis et al., 1993; van Kempen et al., 1992), yielding the 
same bromophenacyl chromophore, require longer reaction time – up to 90 minutes – and 
higher temperatures. 
Derivatization on the hydroxy group of carnitine has been reported for the enantioselective 
separation and quantification of L-carnitine and its isomer D-carnitine (De Witt et al., 1994; 
Mardones et al., 1999). 
Carnitine and acylcarnitines have been coupled to a variety of fluorescent reagents for 
detection: 9-anthryldiazomethane (ADAM) (Yoshida et al., 1988), 3-bromomethyl-6,7-
dimethoxy-1-methyl-2-quinoxalinone (Br-DMEQ) (Kamimori et al., 1994), 4-(2-
aminoethylamino)-7-nitro-2,1,3-benzoxadiazole (NBD-ED) (Matsumoto et al., 1994), 2-(2,3-
naphthalimino) ethyl trifluoromethanesulfonate (Minkler et al., 1995), 1-aminoanthracene 
(Longo et al., 1996) or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) (Cao et al., 
2007). With fluorescence detection, sensitivity is enhanced compared to UV detection with 
a 500-fold gain and limit of detection in the range 10-100 fmol injected (Minkler et al., 1995). 
Radioactivity measurement is another detection method that has been associated with 
HPLC for the determination of carnitine. Hoppel and colleagues applied the radioenzymatic 
assay after HPLC-separation of carnitine and acylcarnitines (Hoppel et al., 1986). The 
acylcarnitine fractions were roughly identified with UV at 210 nm and hydrolyzed under 
alkaline conditions. Carnitine was then quantified as labeled acetylcarnitine, produced by 
the enzyme carnitine acetyltransferase with labeled acetyl-CoA. 
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Tritium labeled carnitine was used for the so-called radioisotopic-exchange method 
(RIE/HPLC) (Kerner et al., 1983; Schmidt-Sommerfeld et al., 1995). The analytes range 
measured depends on the substrate specificity of carnitine acetyltransferase. Tissue 
(Kerner et al., 1983) or plasma samples (Schmidt-Sommerfeld et al., 1995) are in a first 
phase incubated with CAT and 3H-carnitine. Since the enzymatic reaction is reversible, 
acylcarnitines incorporate the labeled carnitine. After equilibration, the reaction is shifted to 
the acylcarnitine side, while trapping CoASH with N-ethylmaleimide. HPLC fractions are 
then analyzed in a -counter. Although specific and precise, these methods have the 
disadvantage of using radioactivity and being time-consuming. 
3.5.4. Capillary electrophoresis 
Capillary electrophoresis (CE) is a separation technique based on the motion of a molecule 
in an electric field. A CE apparatus consists of a capillary containing a buffer and 
connecting two buffer reservoirs subjected to an electric potential. The different charge and 
size of the analytes are determinant for their mobility in the capillary (Li, 1992). Charged 
analytes are particularly well suited for capillary electrophoresis. Carnitine and derivatives 
with their positive charge on the trimethyl ammonium group are good candidates for this 
separation method. 
After electrophoretic separation, the analytes can be detected by several methods such as 
UV spectroscopy (Vernez et al., 2000), fluorescence spectroscopy (Kiessig et al., 1997), 
mass spectrometry (Heinig et al., 1999) or contactless conductivity (Pormsila et al., 2011). 
When using UV or fluorescence spectroscopy, derivatization remains a necessary step to 
introduce a chromophore in the analytes. Similar derivatization agents as for HPLC-UV or 
HPLC-fluorescence have been used (Kiessig et al., 1997; Vernez et al., 2000). The 
detection limits are comparable to the ones obtained with HPLC separation and are situated 
in the low micromolar range. Mass spectrometry and contactless conductivity both have the 
advantage of not requiring any modification of the analyte for its detection. 
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Capillary electrophoresis has been coupled to contactless conductivity detection for the 
simultaneous quantification of carnitine and six acylcarnitines in plasma and urine (Pormsila 
et al., 2011). Based on the conductance between electrodes, detection with capacitively 
coupled contactless conductivity (C4D) is particularly adapted for charged molecules such 
as carnitine. Pormsila and colleagues developed a method with an easy sample workup for 
plasma and urine with detection limits between 1-3 mol/L. With the addition of cyclodextrin 
in the running buffer, carnitine and six acylcarnitines, including the isobaric 
octanoylcarnitine and valproylcarnitine, could be separated within a 7 minutes run. 
Separation with capillary electrophoresis, in comparison to HPLC, has advantages: the 
sample volume and the solvent requirements are typically lower, separation times are 
usually shorter and minimal sample workup is necessary (Heinig et al., 1999; Vernez et al., 
2000). 
3.5.5. Mass spectrometry 
Mass spectrometry has been applied for the qualitative and quantitative determination of 
carnitine and its esters since the 1980s. A first utilization of this technique was reported in 
1984 (Millington et al., 1984). In this study, acylcarnitines from urine samples of children 
with organic acidurias or Reye’s syndrome were ionized with a FAB source. The method 
has been extended to other matrices such as blood, tissue (Millington et al., 1989) or dried 
blood spots (DBS) (Millington et al., 1990). 
With the availability of mass spectrometry, considerable advances have been realized in 
the field of carnitine determination. Mass spectrometry allows the identification and 
elucidation of acylcarnitines as well as their quantification. Thanks to mass spectrometry, 
profiling of acylcarnitines, as marker of metabolic disorders, is widespread for many clinical 
applications, such as new born screening (Chace et al., 2003; Zytkovicz et al., 2001), post-
mortem examinations (Rashed et al., 1995; Roe et al., 1987), prenatal diagnosis (Braida et 
al., 2001; Van Hove et al., 1993) or clinical monitoring (Vernez et al., 2006). 
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Screenings for metabolic disorders were often done in urine (Lowes et al., 1990; Millington 
et al., 1984), with the limitation to renally excreted acylcarnitines. With plasma or blood 
dried on filter paper, protein bound acylcarnitines could be included in the profile. In the 
past years urine analysis has been re-implanted as meaningful tool for the identification of 
some disorders (Duranti et al., 2008; Tortorelli et al., 2005). 
Several ionization sources have been implemented when analyzing acylcarnitines (Briand 
et al., 1995; Millington et al., 1989), the most common being electrospray ionization (ESI) 
(Fingerhut et al., 2001; Vernez et al., 2003). 
Although not essential for the detection with mass spectrometry, derivatization is a common 
step in the sample workup process to increase sensitivity. Typically, carnitine and 
acylcarnitines are derivatized within 15 minutes at 65°C with methanol or butanol, yielding 
methyl or butyl esters respectively (Chace et al., 1997; Inoue et al., 1999). This 
derivatization step can be critical and be source of imprecision. Hydrolysis of the 
acylcarnitines can occur, leading to erroneous results (Johnson, 1999). 
A fragment typically used for carnitine and derivatives in tandem mass spectrometry is 
85 m/z (Figure 4). This fragment is obtained from carnitine and any acylcarnitine after loss of 
the trimethyl amine group and the acyl moiety (Möder et al., 2005). 
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Figure 4: Common fragment of carnitine and derivatives 
 
This common feature has been exploited for screening purposes in the precursor ion mode, 
allowing the identification of a wide range of acylcarnitines (Clayton et al., 1998; Mueller et 
al., 2003). Neutral loss mode with the m/z 59, corresponding to the trimethyl amine, is also 
a fragment common to all acylcarnitines that can be used for the screening of acylcarnitines 
(Zuniga et al., 2011). 
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Mass spectrometry has often been combined to various separation methods to allow the 
differentiation of isobaric compounds with similar fragmentation pattern. The most common 
combination is with HPLC (Minkler et al., 2008; Vernez et al., 2003), while methods using 
capillary electrophoresis (Chalcraft et al., 2009; Heinig et al., 1999) or gas chromatography 
(Lowes et al., 1990) have also been described. Separation prior to detection allowed the 
identification of new metabolites such as valproylcarnitine, isomer of octanoylcarnitine 
(Millington et al., 1985). 
Given the endogenous nature of carnitine and acylcarnitines, classical quantification as 
recommended for a bioanalytical method (FDA, 2001) is not a straight forward process. 
Since most of the biological fluids or tissues contain carnitine, surrogate matrices or 
analytes have often been used. Blank plasma has been mimicked with dialyzed plasma 
(Longo et al., 1996) or bovine serum albumin (BSA) 4% (Minkler et al., 2008; Vernez et al., 
2004), corresponding to a plasma albumin concentration of 40 g/L. Water is a common 
urine ersatz (Maeda et al., 2007; Vernez et al., 2003). Standard curves with deuterated 
standards have been built to circumvent the presence of the analytes in the matrix (Liu et 
al., 2008). In dried blood samples, quantification is often based on the intensity of labeled 
internal standards. 
Semi-quantitative approaches using the ratios of specific acylcarnitines and carnitine 
(Fingerhut et al., 2001; Rashed et al., 1995) are common with defined cut-off values to 
identify pathological conditions. 
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3.6. Carnitine in muscle 
3.6.1. Muscular energy supply 
Any muscular effort requires energy from the hydrolysis of ATP. This ATP can come from 
several sources, such as phosphocreatine, glycogen, and fatty acids (Figure 5). 
Phosphocreatine is a high energy molecule serving as ATP reserve. At the onset of 
exercise, phosphocreatine is rapidly used to generate ATP, a reaction catalyzed by the 
enzyme creatine kinase (Hultman et al., 1991). 
 
 
 
Figure 5: Overview of the ATP producing pathways 
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Glycogen, a branched glucose polymer, is the storage form of glucose. When needed, 
glycogen is broken down to single glucose-6-phosphate units that can enter glycolysis. 
During glycolysis, one glucose molecule is degraded to two pyruvates with net formation of 
two ATP and two NADH + H+. Pyruvate, the end product of glycolysis, is either reduced to 
lactate with concomitant oxidation of NADH to NAD+ or decarboxylated to acetyl-CoA 
entering subsequently the mitochondrial citric acid cycle. While the conversion of pyruvate 
to lactate is anaerobic, the entire processing of acetyl-CoA in the citric acid cycle and in the 
electron transport chain requires the presence of oxygen. 
The main site of fatty acid degradation is the mitochondrion. After translocation in the 
mitochondrial matrix via the carnitine shuttle, long chain fatty acyl-CoAs enter -oxidation. 
In a four-step enzymatic process, they are shortened by C2 acetyl-CoA units. Per cycle of 
-oxidation, one acetyl-CoA is formed, while one FADH2 and one NADH + H
+ are 
generated, both delivering electrons to the electron transport system. 
In the mitochondrion, the citric acid enzymes allow the complete oxidation of the high 
energy acetyl-CoA to CO2 with the production of three NADH, one GTP and one FADH2. 
NADH and FADH2 are two electron transferring substrates involved in the respiratory chain. 
The respiratory chain is the main cellular ATP producing machinery. It is composed of five 
complexes located in the mitochondrial inner membrane (Figure 6). 
Complex I, also known as NADH:coenzymeQ oxidoreductase, catalyzes the electron 
transfer from NADH to ubiquinone, the oxidized form of coenzyme Q, by the intermediary of 
flavin mononucleotide (FMN) and iron-sulfur clusters. 
Complex II, the succinate:coenzyme Q oxidoreductase, transfers electrons from succinate 
to ubiquinone via flavin adenine dinucleotide (FAD) and iron-sulfur clusters. FAD is a 
prosthetic group reduced during the oxidation of succinate to fumarate by the succinate 
dehydrogenase, part of the citric acid cycle and complex II. 
The electrons of ubiquinol, the reduced form of coenzyme Q, are processed in complex III, 
the coenzyme Q:cytochrome C reductase. Via hemes and an iron-sulfur cluster, electrons 
are transferred from ubiquinol to cytochrome c, a peripheral membrane protein of the inner 
mitochondrial membrane. 
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The last complex of the electron transport chain is the cytochrome c oxidase, complex IV. 
By the intermediary of hemes and copper containing centers, electrons from cytochrome c 
are transferred to molecular oxygen, yielding water. 
 
 
 
Figure 6:The respiratory chain (adapted from Cuperus et al., 2010) 
 
During the electron transport process, from NADH and FADH2 to oxygen, protons are 
pumped from the mitochondrial matrix into the intermembrane space, creating an 
electrochemical gradient. The proton gradient drives complex V, also called F1F0-ATP 
synthase, generating ATP. Complex V functions as a rotor, converting the chemical energy 
of the proton gradient into mechanical energy (Voet et al., 2004). 
3.6.2. Muscle types 
The energy source of a contracting muscle depends on the exercise intensity. A long and 
moderate effort tends to be mainly supplied by lipid oxidation whereas a short and intense 
effort is powered by glucose degradation (van Loon et al., 2001). 
In the regulation between the aerobic and anaerobic energetic pathways, the pyruvate 
dehydrogenase complex (PDC) plays a pivotal role. It catalyzes the decarboxylation of 
pyruvate to acetyl-CoA with concomitant reduction of NAD+. The phosphorylation state of 
PDC and the inhibitory effect of its products acetyl-CoA and NADH regulate the activity of 
PDC and the acetyl-CoA flux towards the citric acid cycle (Greenhaff et al., 2002). 
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The energy supply depends also on the type of the muscle. According to their 
morphological and physiological characteristics –ATPase activity, myosin heavy chain type 
or succinate dehydrogenase content– muscle fibers have been divided into three main 
categories: type I, type IIA and IIB fibers. The proportion of fiber types in a given muscle 
shows interspecies and interindividual variability. 
Type I fibers are slow oxidative fibers, relying on lipid oxidation as their main source of ATP. 
These fibers are fatigue resistant and are typically found in postural muscles. They contain 
a high mitochondrial volume and a rich pool of oxidative enzymes, supplied in oxygen by a 
dense capillary network. Because of their high amount of myoglobin for the transport of 
oxygen, type I fibers are typically red. 
Type II fibers rely mostly on glucose for their energy supply. These fibers are fast at 
producing energy but are more fatigue-prone than type I fibers. Type II fibers contain high 
levels of glycolytic enzymes and glycogen. They require lower oxygen concentrations, 
explaining their white color. Type II fibers are subdivided into type IIA and IIB. Type IIA 
fibers are relatively fatigue resistant and besides the glycolytic machinery contain also 
oxidative enzymes, as revealed by a strong succinate dehydrogenase (SDH) staining. They 
are referred to as fast-twitch oxidative glycolytic fibers. Type IIB fibers, the fast-twitch 
glycolytic fibers, are practically devoid of oxidative enzymes and are quickly fatigable. Other 
type II fibers subtypes have been described with characteristics between type IIA and type 
IIB (Schiaffino et al., 2011). 
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3.6.3. Carnitine and muscle function 
Due to its position at strategic points in energy metabolism, carnitine has been the focus of 
many studies investigating muscle function and performance. On the one hand, as fatty 
acid importer, carnitine could enhance fatty acid oxidation, thereby potentially sparing 
glycogen reserves. CPT1, the rate limiting step of -oxidation, with a Km value of about 
0.5 mM for carnitine (McGarry et al., 1983) is under resting conditions saturated (muscle 
concentrations 2-4 mmol/kg wet weight). While the total muscular carnitine content is barely 
affected during exercise, the free carnitine to acylcarnitines ratio can dramatically change. 
At rest or during low intensity exercise, acylcarnitines, especially acetylcarnitine, represent 
10-20% of the total carnitine pool, with about 80% of free carnitine. After exhaustive 
exercise, the acetylcarnitine concentration increases, accounting for more than 60% of the 
total carnitine content (Constantin-Teodosiu et al., 1996). Under these conditions and 
considering possible compartment differences, carnitine availability might become a limiting 
factor for the activity of CPT1 (Jeppesen et al., 2012; Stephens et al., 2007a). 
On the other hand, as acetyl-CoA buffering agent, carnitine could enhance the PDC flux 
while lowering the acetyl-CoA to CoA ratio. An increased turnover of pyruvate by PDC 
would in turn reduce lactate formation (Brass, 2000). 
Many studies assessing potential effects of carnitine on muscle function exist. While the 
benefits of carnitine on muscle function in pathological states are positively documented, 
the situation in healthy volunteers is controversial (Brass, 2004). 
Most studies conducted in humans failed to show a clear impact of carnitine 
supplementation on muscle carnitine concentrations, respectively on muscle performance. 
Whether oral or intravenous, doses up to 4 g generally did not affect the muscular carnitine 
pool, even though increasing the plasma concentrations (Stephens et al., 2007a). Markers 
of muscle metabolism (lactate, glycogen content) or markers of performance (VO2 max, 
respiratory quotient) are often unaffected by a supplementation. Reported positive results 
concern mostly one metabolic marker and are not consistent between the studies (Brass, 
2004). Divergent results can partly be attributed to broad differences in study designs in 
terms of exercise, type, dose and duration of supplementation, training status of the 
subjects and control of dietary carnitine (Galloway et al., 2005). 
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Recently, Stephens and coworkers highlighted the enhancing effect of hyperinsulinemia on 
the carnitine muscle concentration. With direct insulin infusion or carbohydrate-induced 
hyperinsulinemia, the carnitine levels could be increased by 10 to 15% in muscle (Stephens 
et al., 2006; Stephens et al., 2007c). The effects of such an elevation were investigated in 
14 healthy volunteers supplemented with 2 g of carnitine twice daily with 80 g 
carbohydrates or placebo during 12 or 24 weeks. Wall and colleagues reported a 20% 
increase of carnitine muscle concentration, associated with a diminished lactate, increased 
glycogen and enhanced PDC activity in muscle at 80% VO2 max. These effects were 
observed only after the longer period of supplementation (Wall et al., 2011). This study 
supports the dual effect of carnitine in muscle function, as lipid oxidation enhancer at low 
intensity exercise and as PDC indirect activator during high intensity workout. 
Acetylcarnitine and propionylcarnitine are two short chain carnitine derivatives. Both 
substances have been studied for several indications; acetylcarnitine shows beneficial 
effects in cognition while propionylcarnitine has a protective effect in heart failure and 
ischemia-reperfusion studies. Their potential advantages over carnitine as exercise 
enhancers are unknown (Galloway et al., 2005). 
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4. AIMS OF THE THESIS 
The general aim of this thesis is to highlight the importance of carnitine from a physiological 
and from an analytical point of view. This thesis had three specific aims developed in three 
projects. 
The aim of the first project was to gain a better insight into the carnitine homeostasis under 
valproate therapy with focus on the metabolite valproylcarnitine. We aimed to understand 
the molecular mechanism leading to or counteracting a renal loss of carnitine in patients 
treated with valproate. We performed uptake experiments in cells overexpressing OCTN2, 
the main transporter responsible for the renal reabsorption of carnitine and investigated the 
transport of radiolabeled carnitine in presence of valproylcarnitine. In parallel, we conducted 
a study with one patient starting a therapy with valproate and with ten patients under long 
term therapy with this drug. In plasma and urine samples we determined the concentrations 
and clearances of carnitine and several acylcarnitines including valproylcarnitine as well as 
the carnitine precursor butyrobetaine. 
The goal of the second project was to optimize a LC-MS/MS method for the simultaneous 
determination of carnitine and acylcarnitines in plasma. For a rapid determination, we 
performed an online solid phase extraction on a cation exchange column before elution on 
the analytical column. For quantification, we applied the addition method to account for 
matrix effects and work in native matrix, containing endogenous analytes. 
The third project aimed to investigate the benefits of acylcarnitines supplementation on the 
muscular capacity of mice in vivo. After oral supplementation with carnitine, acetylcarnitine 
or propionylcarnitine, mice completed a treadmill exercise until exhaustion. We investigated 
the mitochondrial function in skeletal muscle fibers with high resolution respirometry. 
Energy parameters such as lactate, glycogen, creatine, and phosphocreatine were 
determined. Carnitine concentrations in plasma, urine and muscles were analyzed and total 
carnitine balance was assessed. 
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5.1. Abstract 
Aims: To identify mechanisms of hypocarnitinemia in patients treated with valproate. 
Methods: Plasma concentrations and urinary excretion of carnitine, acetylcarnitine, 
propionylcarnitine, valproylcarnitine, and butyrobetaine were determined in a patient 
starting valproate treatment and in 10 patients on long-term valproate treatment. Transport 
of carnitine and valproylcarnitine by the proximal tubular carnitine transporter OCTN2 was 
assessed in vitro. 
Results: In the patient starting valproate, the plasma carnitine and acetylcarnitine levels 
dropped for 1 to 3 weeks and had recovered after 3 to 5 weeks, whereas the plasma levels 
of propionyl- and valproylcarnitine increased steadily over 5 weeks. The renal excretion and 
excretion fractions (EF) of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine 
decreased substantially after starting valproate. Compared to controls, patients on long-
term valproate treatment had similar plasma levels of carnitine, acetylcarnitine and 
propionylcarnitine, whereas valproylcarnitine was found only in patients. Urinary excretion 
and renal clearance of carnitine, acetylcarnitine, propionylcarnitine and butyrobetaine were 
decreased in valproate-treated compared to control patients, reaching statistical 
significance for carnitine. The EFs of carnitine, acetylcarnitine and propionylcarnitine were 
<5% of the filtered load in controls and were lower in valproate-treated patients. In contrast, 
the EF for valproylcarnitine approached 100%, resulting from a low affinity of 
valproylcarnitine for the carnitine transporter OCTN2 and competition with concomitantly 
filtered carnitine. 
Conclusions: The initial drop in plasma carnitine levels of valproate-treated patients is most 
likely due to impaired carnitine biosynthesis, whereas the recovery of the plasma carnitine 
levels is explainable by increased renal expression of OCTN2. Renally excreted 
valproylcarnitine does not affect renal handling of carnitine in vivo. 
 
Key words: valproate, carnitine, valproylcarnitine, OCTN2, carnitine biosynthesis 
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5.2. Introduction 
Valproic acid (valproate) is a branched, medium-chain fatty acid frequently used as an 
antiepileptic drug (Beydoun et al., 1997; Marson et al., 2007) and, more recently, also for 
the prophylaxis of migraine and in patients with bipolar disorder (Bond et al., 2010; 
D'Amico, 2010). Valproate is primarily metabolized by glucuronidation (DeVane, 2003) A 
smaller part is transformed to the coenzyme A derivative, which can either be converted to 
the respective carnitine ester or -oxidized to propionyl-CoA and acetyl-CoA. Accordingly, 
valproylcarnitine has been detected in the plasma and in urine of patients treated with 
valproate (Millington et al., 1985; Murakami et al., 1996; Muro et al., 1995). 
Already more than 20 years ago, first reports have been published about children treated 
with valproate who have decreased free carnitine plasma concentrations (Bohles et al., 
1982; Ohtani et al., 1982; Stumpf et al., 1983). Since hypocarnitinemia can be associated 
with hyperammonemia, this is a potentially severe complication of this treatment (Eubanks 
et al., 2008; Hamed et al., 2009; Thom et al., 1991). Interestingly, not all patients treated 
with valproate develop hypocarnitinemia (Coppola et al., 2006; Hirose et al., 1998). In 
children with long-term valproate ingestion, the frequency of hypocarnitinemia has been 
reported to be in the range of 40% (Coppola et al., 2006), whereas hypocarnitinemia is less 
frequent in adolescents or adults treated with this drug (Silva et al., 2001). Accordingly, 
reported risk factors for hypocarnitinemia in valproate-treated patients include valproate 
dose, young age and antiepileptic polytherapy (Coppola et al., 2006; Hamed et al., 2009; 
Thom et al., 1991). 
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Carnitine is a small molecule which is essential for the transport of long-chain fatty acids in 
the mitochondrial matrix, where they can be -oxidized (Fritz, 1955; Fritz et al., 1965; 
Kerner et al., 2000). Beside this, carnitine is important to maintain a sufficiently high 
intracellular concentration of coenzyme A, which is used in many metabolic pathways 
(Brass et al., 1980; Friolet et al., 1994). The acyl-groups of acyl-CoAs can be transferred to 
carnitine by the action of acylcarnitine transferases, leading to the formation of the 
respective acylcarnitine (Bremer, 1983; Kerner et al., 2000). In contrast to acyl-CoAs, 
acylcarnitines can be transported out of cells and can be excreted by the urine. By this 
mechanism, potentially toxic acyl-groups can be eliminated (Vernez et al., 2006). Carnitine 
is eliminated by glomerular filtration (Heuberger et al., 1998), but most of the carnitine 
filtered is reabsorbed by the action of the carnitine carrier OCTN2 (Bremer, 1983; 
Krahenbuhl et al., 2000; Krahenbuhl et al., 1997), which is located in the proximal tubule 
(Haschke et al., 2010; Nezu et al., 1999; Todesco et al., 2008). In mammals, most of the 
carnitine body needs are provided by the diet, and a smaller part is biosynthesized in 
skeletal muscle, liver and kidneys (Krahenbuhl et al., 2000; Vaz et al., 2002a). 
The precise mechanisms leading to hypocarnitinemia in patients treated with valproate are 
so far not known. Stadler et al. assessed urinary carnitine excretion during the first month of 
treatment with valproate (Stadler et al., 1999). Interestingly, they found an initial drop in the 
free carnitine plasma concentration, followed by a complete recovery after one month of 
treatment. The renal clearance of carnitine first increased and then decreased compared to 
the pre-treatment values, offering a possible explanation for changes in the plasma 
carnitine concentrations. In addition, Farkas et al. reported a decrease in carnitine 
biosynthesis in rats treated with valproate (Farkas et al., 1996), offering an alternative 
explanation for hypocarnitinemia in patients treated with valproate. 
The current study was performed to define better the molecular mechanisms leading to 
hypocarnitinemia in patients treated with valproate as well as to explore potential 
mechanisms counteracting the renal loss of carnitine in such patients. We therefore 
investigated the renal handling of valproylcarnitine and free carnitine in patients treated with 
valproate and performed in vitro investigations regarding transport of valproylcarnitine by 
OCTN2 and expression of OCTN2 in the presence of valproate. 
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5.3. Materials and Methods 
Reagents 
L-Carnitine, acetylcarnitine, and sodium valproate were purchased from Sigma (St. Louis, 
MO, USA). Propionylcarnitine and valproylcarnitine were obtained from Dr. H. J. ten Brink 
(VU Medical Center, Amsterdam, The Netherlands). Carnitine-d3 and octanoylcarnitine-d3 
were supplied by Cambridge Isotope Laboratories (Andover, MA, USA) and 3H-L-carnitine 
by GE Healthcare (Amersham, UK). All other chemicals and solvents were from Merck 
(Darmstadt, Germany) or Sigma. 
Collection of plasma and urine samples 
Blood was collected by venopuncture into heparinized tubes from one patient immediately 
before and at several occasions after starting treatment with valproate, from 10 patients on 
long-term treatment (>1 month) with valproate and from 10 age- and sex-matched control 
patients not treated with valproate. Plasma was obtained by centrifugation and stored at 
-70°C until analysis. 
From the patient studied during start of therapy with valproate, spot urine samples were 
obtained when blood samples were drawn. Valproate plasma levels were determined by an 
enzyme immunoassay routinely used in the University Hospital. From the patients on long-
term valproate treatment and from the corresponding control patients, 24-hour urine 
samples were obtained when the venous blood samples were drawn. The volume of the 
urine was determined, and a urine sample was stored at -70°C until analysis. The Ethics 
Committee of the State of Basel had approved the study protocol. 
Synthesis of 3H-valproylcarnitine 
The synthesis and purification of 3H-valproylcarnitine was performed according to the 
procedure of Ziegler et al. (Ziegler et al., 1967) and the patent 7916590 of Sigma-Tau with 
the modifications described previously for pivaloylcarntine (Todesco et al., 2009). The 
product was analyzed with NMR in deuterated methanol as described (Todesco et al., 
2009). 3H-valproylcarnitine was 96.5% pure; the 3.5% impurity was not carnitine. 
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LC/MS-MS Equipment 
The HPLC system consisted of a HTS PAL autosampler (CTC Analytics AG, Zwingen, 
Switzerland), an oven (CTO-20A), pumps (LC-20AD) and a controller (CBM-20A) from 
Shimazu (Reinach, Switzerland). The HPLC system was coupled to a triple quadrupole 
mass spectrometer API 4000 (AB/MDS Sciex, Concord, Canada) with an electron spray 
ionization source. Separation was performed on a Luna C8 5 m column (150mm x 2mm) 
equipped with a C8 (4 x 2.0 mm) precolumn (Phenomenex, Torrance, CA, USA). 
Preparation of samples and calibrators, HPLC conditions 
Samples and calibrators were prepared as described previously by Vernez et al.(Vernez et 
al., 2003; Vernez et al., 2004). The chromatographic separation was done with a binary flow 
(0.2 mL/min) at 30°C. Starting at 20% phase B, the gradient increased to 90% phase B 
within 8 minutes. After a 5 minutes plateau at 90% phase B, the analytical column was 
re-equilibrated for 3 minutes with 20% B, for a total run time of 16 minutes. 
MS conditions and validation 
Carnitine and the acylcarnitines of interest were analyzed in the multiple reaction monitoring 
mode. A first transition was used for quantification, a second one for qualification. Following 
transitions (m/z) were used: butyrobetaine 146→87, 146→60 carnitine 162→105, 162→85; 
carnitine-d3 165→103, 165→85; acetylcarnitine 204→85, 204→145; propionylcarnitine 
218→85, 218→159; valproylcarnitine 288→85, 288→229; octanoylcarnitine-d3 291→85, 
291→229. 
Imprecision and accuracy were assessed with three quality controls (QC) measured on 
several days (n=5). The concentrations used for carnitine were 3.75, 37.5, and 150 mol/L, 
for acetylcarnitine 2, 10, and 40 mol/L, and for the other analytes 0.2, 1, and 4 mol/L. In 
plasma, inter-assay precisions for the QC concentrations were ≤6.0% for all measured 
analytes and the inter-day accuracies were between 92.9 and 105.5%. For urine, the 
precision was ≤7.8% for carnitine and valproylcarnitine and ≤14.5% for the other analytes. 
The accuracy was within 87.9-113.6% for all compounds. The standard curves showed an 
excellent linearity for all analytes tested both in plasma and urine (r2 ≥0.993). 
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Transport of carnitine and valproylcarnitine by OCTN2 
Uptake experiments were conducted in L6 cells (rat skeletal muscle myoblasts) 
overexpressing human OCTN2 (hOCTN2) exactly as described before (Todesco et al., 
2008). The protein content was determined with the Pierce Chemical BCA kit (Rockford, IL, 
USA) as specified by the supplier. 
Expression of OCTN2 mRNA in HEK293-FT cells 
HEK293-FT cells (human embryonic kidney cells) were supplied by Invitrogen (Paisley, 
UK). Growth medium (DMEM high glucose) contained 10% FBS, 1% Glutamax, 1% 
HEPES, 100 U/mL penicillin, and 100 g/mL streptomycin. Cells were grown in 6-well 
plates and treated when they reached 60-70% confluency. Valproate 100 or 1000 mol/L, 
valproylcarnitine 5 mol/L, or DMSO as control was added to the cell culture medium. 
After 6h, 24h or 48h of treatment, RNA was collected and purified with the RNeasy Mini Kit 
(Qiagen, Hombrechtikon, Switzerland) according to the supplier’s procedure. RNA was then 
converted to cDNA with the Omniscript RT Kit (Qiagen Hombrechtikon, Switzerland). 
Amplification and detection were made on an ABI Prism 7900HT RT-PCR machine (Applied 
Biosystems, Rotkreuz, Switzerland) with the FastStart SYBR green Master (Roche, Basel, 
Switzerland). The expression of OCTN2 and GAPDH was investigated. Primers were 
purchased from Microsynth (Balgach, Switzerland) and designed as follows: hOCTN2 
forward primer 5'-GCAGCATCCTGTCTCCCTAC-3', reverse primer 5'-
GCTGTCAGGATGGTCAGACTT-3', and GAPDH forward primer 5'-
AGCCACATCGCTCAGACAC-3', reverse primer 5'-GCCCAATACGACCAAATCC-3'. 
Quantification of OCTN2 mRNA levels was performed with GAPDH as an endogenous 
control with the comparative threshold cycle method. The results are expressed relative to 
the values obtained in control cells at 6h, 24h and 48h respectively. 
Protein expression of OCTN2 in HEK293-FT cells 
After incubation in 6-well plates, the cells were trypsinized and washed twice with ice cold 
PBS. The cell pellet was lysed with 100 L NET lysis buffer (50 mmol/L Tris-HCl, 50 mmol/L 
NaCl, 5 mmol/L EDTA, 1% NP-40, and Complete Mini anti-protease cocktail (Roche, 
Switzerland)) for 15 minutes on ice. The lysate was centrifuged at 15’700 g for 10 minutes 
at 4°C. 
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After protein determination, the supernatant was combined with NuPage LDS sample buffer 
(Invitrogen, Paisley, UK) and heated during 5 minutes at 95°C. The proteins were 
separated on a NuPage 4–12% Bis-Tris gel (Invitrogen) and then blotted on a PVDF 
membrane (Millipore, Zug, Switzerland) in a semi-dry transfer cell (BioRad, Reinach, 
Switzerland). The membrane was blocked with a 5% milk protein solution in PBS for 1 hour, 
washed and incubated with the primary antibody OCTN2/K33 (1:5000) (Todesco et al., 
2008) or β-actin (1:2000) (Santa Cruz Biotechnology, CA, USA) overnight at 4°C. After 
washing, the membrane was incubated with the HRP-coupled secondary antibody, goat 
anti-rabbit for OCTN2 and rabbit anti-goat for -actin (BioRad, Reinach, Switzerland). 
Detection was made with the ECL Western blotting reagents (GE Healthcare, Amersham, 
UK). Quantification of OCTN2 was made with the Quantity One software (BioRad) relative 
to β-actin. 
Statistics and calculations 
The renal clearance (Clren) and the renal excretion fractions of carnitine and acylcarnitines 
were determined as described previously (Haschke et al., 2010; Heuberger et al., 1998). 
Curve fitting of the uptake experiments and determination of the kinetic parameters were 
done with SigmaPlot® version 11 (Scientific Solutions, Lausanne, Switzerland) as 
described previously (Todesco et al., 2009). 
Median values of the 2 groups were compared with the rank sum test using SigmaStat 
version 3.5 (Scientific Solutions, Lausanne, Switzerland). 
5.4. Results 
Carnitine metabolism and urinary excretion in a patient starting treatment with valproate 
We first determined the renal handling of carnitine in a 28-years old omnivore female during 
the initial five weeks after starting a treatment with valproate. Similar to a report in the 
literature (Stadler et al., 1999), the plasma carnitine concentration showed an initial drop 
and then gradually recovered, reaching pre-treatment values after one month of treatment 
(Figure 1A and 1B). The plasma acetylcarnitine and butyrobetaine concentrations showed a 
similar behavior as carnitine with a more accentuated initial drop for acetylcarnitine. In 
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contrast, the plasma concentrations of valproylcarnitine and propionylcarnitine increased 
with time and correlated with the plasma valproate concentration. 
 
 
Figure 1: Plasma concentrations and renal handling of carnitine, acylcarnitines and butyrobetaine in a patient starting 
treatment with valproate. (A) After an initial drop, the plasma concentrations of carnitine and acetylcarnitine 
recover during treatment with valproate. (B) The plasma concentrations of valproylcarnitine and 
propionylcarnitine (both formed from valproyl-CoA) increase with rising valproate concentrations. (C) The 
renal excretions of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine show a sharp drop after 
starting valproate treatment, whereas the excretion of valproylcarnitine increases. (D) The excretion fractions 
of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine decrease after starting valproate treatment, 
whereas the excretion fraction of valproylcarnitine is in the range of 150 to 250%. 
 
 
In order to detect possible reasons for the initial drop in the plasma carnitine and 
acetylcarnitine concentrations, we determined the renal excretion of carnitine, 
acylcarnitines, and butyrobetaine in this patient. As shown in Figure 1C, the urinary excretions 
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of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine dropped after starting the 
treatment with valproate, whereas the excretion of valproylcarnitine steadily increased with 
the duration of exposure. The excretion fractions of carnitine, acetylcarnitine, 
propionylcarnitine, and butyrobetaine were <5% of the filtered load before and, in 
agreement with the reduced renal excretion of these compounds, decreased by 50% or 
more during treatment with valproate. While the excretion of valproylcarnitine was 
approximately 50 times lower compared to carnitine, the excretion fraction of 
valproylcarnitine remained constant between 150 and 250% of the filtered load during 
treatment with valproate (Figure 1D). 
Transport of carnitine and valproylcarnitine by OCTN2 
The results obtained in the patient described above clearly indicated that the initial drop in 
the carnitine plasma concentration could not be explained by increased renal losses of 
carnitine, acylcarnitines or butyrobetaine. In order to understand better the high excretion 
fraction of valproylcarnitine and to investigate a possible interaction between 
valproylcarnitine and carnitine at the level of OCTN2, we studied the transport of 
valproylcarnitine and its interaction with carnitine in L6 cells overexpressing hOCTN2. As 
reported previously (Todesco et al., 2009; Todesco et al., 2008), the transport of L-carnitine 
displayed a saturable Michael-Menten kinetics with a Km of 11.9 ± 1.5 μmol/L and a Vmax of 
263 ± 14 pmol x mg protein-1 x min-1 (mean ± SD, Figure 2A). Valproylcarnitine inhibited the 
transport of carnitine competitively with a Ki of 78.5 ± 8.6 μmol/L (Figure 2A and B). 
Valproylcarnitine was also transported by OCTN2; the maximal transport activity was 
similar to L-carnitine (Vmax 287 ± 9 pmol x protein
-1 x min-1), but the affinity for hOCTN2 was 
much lower (Km 218 ± 20 mol/L) (Figure 2C). L-carnitine inhibited the transport of 
valproylcarnitine competitively with a Ki of 12.5 ± 0.9 μmol/L (Figure 2C and D). 
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Figure 2: Transport of carnitine and valproylcarnitine into L6 cells overexpressing hOCTN2. (A) The transport 
of L-carnitine (Km 11.9 ± 1.5 μmol/L) into L6 cells is inhibited by valproylcarnitine. (B) A Dixon plot of this 
transport is compatible with competitive inhibition by valproylcarnitine (K i 78.5 ± 8.6 μmol/L). (C) 
Valproylcarnitine is also transported by OCTN2, but with a low affinity (Km 218 ± 20 μmol/L). Carnitine inhibits 
the transport of valproylcarnitine. (D) The inhibition by L-carnitine is competitive (Ki 12.5 ± 0.9 μmol/L). Values 
are indicated as mean ± SD. 
 
Plasma carnitine and butyrobetaine concentrations in patients on long-term therapy with 
valproate 
To get a better understanding of the effects of long-term treatment with valproate on 
carnitine metabolism, we determined carnitine, acylcarnitines and butyrobetaine in one 
plasma sample and in 24h-urine of ten patients treated with valproate for at least one month 
and ten age- and sex-matched control patients not treated with valproate. Fourteen females 
(7 in each group) and six males (3 per group) were studied. In the valproate group, four 
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patients had valproate for the indication epilepsy and six for mood disorders. The median 
age of the patients in the valproate group was 40 years (range 23-53) and in the control 
group 39 years (range 26-52). The median BMI and body weight were 24.9 kg/m2 (range 
18.0-35.4) and 73 kg (range 49-102), respectively, in the valproate group and 22.1 kg/m2 
(range 17.6-32.5) and 65 kg (range 49-94), respectively, in the control group. 
 
 Control patients (n=10) Valproate-treated 
patients (n=10) 
p 
Carnitine 35.5 (19.0 – 58.0) 34.3 (13.7 – 45.7) 0.734 
Acetylcarnitine 5.17 (3.49 – 11.2) 4.99 (3.70 – 6.70) 0.910 
Propionylcarnitine 0.37 (0.19 – 0.60) 0.52 (0.24 – 1.04) 0.088 
Valproylcarnitine <0.01 0.02 (0.01 – 0.09) <0.001 
Butyrobetaine 0.59 (0.45 – 1.05) 0.54 (0.42 – 0.90) 0.521 
 
Table 1: Carnitine, acylcarnitines and butyrobetaine plasma concentrations in patients on long-term treatment 
with valproate. Carnitine, acylcarnitines and butyrobetaine were determined using LC/MS-MS as described in 
Methods. Data are presented as median (range), units are µmol/L. 
 
As shown in Table 1 and Figure 3A, the inter-individual carnitine and acylcarnitines 
concentrations showed a large variation, not only between, but also within the groups. We 
found no significant differences in the concentrations of carnitine and acetylcarnitine 
between valproate-treated and control patients. Propionylcarnitine concentrations showed a 
trend to be higher in valproate-treated patients, but this increase did not reach statistical 
significance. Valproylcarnitine (median plasma concentration 20 nmol/L) was detectable in 
every patient treated with valproate, but in none of the controls. There were no significant 
correlations between carnitine and propionylcarnitine (Figure 3A), carnitine and 
valproylcarnitine (Figure 3B), total valproate and valproylcarnitine (Figure 3C), and 
valproylcarnitine and propionylcarnitine (Figure 3D). 
The plasma concentration of the carnitine precursor butyrobetaine was approximately 10% 
lower in valproate-treated compared to control patients, but this difference did not reach 
statistical significance (Table 1). 
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Figure 3: Plasma concentrations and correlations of carnitine, propionylcarnitine and valproylcarnitine in 
patients with long-term valproate treatment. (A) There is no significant correlation between carnitine and 
propionylcarnitine in patients treated with valproate (n = 10) and in age and sex matched control patients (n = 
10). (B) There is no significant correlation between carnitine and valproylcarnitine in valproate-treated 
patients. (C) There is no significant correlation between valproate and valproylcarnitine in valproate-treated 
patients. (D) There is no significant correlation between valproylcarnitine and propionylcarnitine in valproate-
treated patients. 
Urinary excretion and clearance of carnitine 
As shown in Table 2, the renal excretion of carnitine and acetylcarnitine were 4 to 5 times 
lower in valproate-treated patients, reaching statistical significance for carnitine. Similar to 
plasma, valproylcarnitine could not be detected in the urine of control patients, but in all the 
samples of patients treated with valproate. Similar to carnitine, the excretion of 
butyrobetaine was also lower in valproate-treated than control patients, but without reaching 
statistical significance. 
  47 
The renal clearances of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine 
averaged all <15 mL/min and the medians were all numerically lower in valproate-treated 
compared to control patients, reaching statistical significance for carnitine (Table 2). In 
comparison, the clearance of valproylcarnitine, which could be calculated only in patients 
treated with valproate, was almost as high as the creatinine clearance. 
 Control patients (n=10) 
Valproate-treated patients 
(n=10) 
P 
Carnitine and butyrobetaine excretion (µmol/day) 
Carnitine 70.8 (5.1 – 454) 14.8 (5.7 – 119) 0.038 
Acetylcarnitine 26.0 (1.2 – 84.8) 6.1 (1.2 – 44.0) 0.162 
Propionylcarnitine 1.19 (0.09 – 6.15) 0.83 (0.12 – 9.55) 0.734 
Valproylcarnitine <0.01 3.01 (0.90 – 8.12) <0.001 
Butyrobetaine 2.71 (1.15 – 13.5) 1.67 (0.57 – 6.73) 0.186 
Renal clearances (mL/min) 
Carnitine 1.53 (0.12 – 8.48) 0.39 (0.11 – 2.14) 0.014 
Acetylcarnitine 3.05 (0.21 – 13.7) 0.82 (0.20 – 6.70) 0.212 
Propionylcarnitine 2.22 (0.24 – 11.5) 0.97 (0.23 – 6.36) 0.521 
Valproylcarnitine n.d. 72.5 (49.1 – 213) n.d. 
Butyrobetaine 3.27 (1.06 – 8.93) 2.22 (0.53 – 5.49) 0.241 
Renal excretion fraction (% of creatinine clearance) 
Carnitine 1.52 (0.10 – 4.54) 0.43 (0.12 – 1.68) 0.031 
Acetylcarnitine 2.77 (0.18 – 7.35) 1.04 (0.27 – 7.64) 0.385 
Propionylcarnitine 1.87 (0.20 – 6.18) 1.63 (0.24 – 5.88) 0.791 
Valproylcarnitine n.d. 88.7 (39.9 – 233) n.d. 
Butyrobetaine 3.11 (1.39 – 5.90) 2.44 (1.36 – 5.79) 0.473 
n.d.: not determinable 
Table 2: Renal handling of carnitine, acylcarnitines and butyrobetaine in patients on valproate long-term 
treatment. Carnitine, acylcarnitines and butyrobetaine were determined using LC/MS-MS as described in 
Methods. The plasma creatinine concentrations and the creatinine clearance were 69 (45 – 91) mol/L and 
106 (76 – 187) mL/min, respectively, in control and 65 (47 – 79) mol/L, and 90 (34 – 163) mL/min, 
respectively, in valproate-treated patients. Data are presented as median (range). 
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The excretion fractions of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine 
were all <10% and the medians of the excretion fractions were all numerically lower in 
valproate-treated compared to control patients, again reaching statistical significance only 
for carnitine (Table 2). For valproylcarnitine, the excretion fraction was in the range of 100%, 
suggesting that filtered valproylcarnitine is not reabsorbed. 
Effect of valproate on hOCTN2 mRNA and protein expression in HEK293 cells 
To investigate the possibility that valproate or valproylcarnitine influence the expression of 
OCTN2, we determined mRNA levels of OCTN2 in the human embryonic kidney cell line 
HEK293 treated with valproate or valproylcarnitine. After 24h of treatment, 100 µmol/L and 
1000 µmol/L valproate significantly enhanced the mRNA expression of OCTN2 by 15 and 
21%, respectively, compared to control values (Figure 4A). At 48h, the corresponding 
increases were 20% and 11% in the presence of 100 and 1000 µmol/L valproate, 
respectively, and did not reach statistical significance. Treatment with 5 µmol/L 
valproylcarnitine was ineffective. 
As shown in Figure 4B, both valproate (100 and 1000 µmol/L) and valproylcarnitine 
(5 µmol/L) did not influence the hOCTN2 protein levels after 24h and 48h of treatment. 
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Figure 4: Effect of valproate and valproylcarnitine on the expression of OCTN2 in HEK293-FT cells. Cells 
were treated with valproate (VPA) 100 or 1000 mol/L or valproylcarnitine (VCn) 5 mol/L for 6h, 24h and 
48h. (A) mRNA expression was measured by quantitative RT-PCR with GAPDH as a control. Expression in 
treated cells is shown relative to the expression in DMSO control cells. The results are the mean of 5 
experiments done in triplicates. In cells treated for 24 h with 100 to 1000 mol/L valproate, the OCTN2 mRNA 
expression is significantly increased by 15 to 21% compared to control values. (B) Representative Western 
blot showing OCTN2 (67 kDa) and -actin (43 kDa) in treated cells. Treatment with VPA or VCn is not 
associated with a change in the OCTN2 protein content. 
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5.5. Discussion 
The investigations in the patient starting treatment with valproate showed two effects on the 
plasma carnitine and acetylcarnitine concentrations: an initial drop reaching its maximum at 
week 1 or 2 and a slow recovery which was achieved between week 3 and 5. Similar 
results have been reported by Stadler et al. (Stadler et al., 1999), who determined carnitine 
plasma concentrations and renal excretion in healthy adults treated with valproate for 28 
days. Similar to our findings, Stadler et al. also observed a reduction in the clearance of 
total and free carnitine, which they claimed to be responsible for the recovery of the plasma 
carnitine concentration after the initial drop (Stadler et al., 1999). 
Since we were able to determine the relevant acylcarnitines and the carnitine precursor 
butyrobetaine, we could not only confirm the results of Stadler et al. (Stadler et al., 1999), 
but we can discuss possible mechanisms underlying the changes in carnitine metabolism 
associated with valproate. The initial drop in the carnitine and acetylcarnitine plasma 
concentrations can theoretically be explained by a reduced intake and/or biosynthesis, an 
increased uptake by tissues (mainly skeletal muscle, the main carnitine store in mammals 
(Bremer, 1983; Friolet et al., 1994; Krahenbuhl et al., 2000)) and/or an increased renal 
excretion. Decreased dietary intake of carnitine can be excluded, since both in the current 
study as well as in the study of Stadler et al. (Stadler et al., 1999) the subjects studied did 
not change their eating habits. Increased renal excretion of carnitine and/or acetylcarnitine 
could be observed in none of the two studies, excluding also this possibility. In the current 
study, the renal excretion of carnitine, acetylcarnitine and propionylcarnitine decreased 
dramatically within the first week after starting treatment with valproate and was low also 
during long-term valproate treatment. The only carnitine species with a higher renal 
excretion compared to pretreatment conditions or patients not treated with valproate was 
valproylcarnitine, which could be detected only in subjects treated with valproate. The renal 
excretion of valproylcarnitine is low compared to the excretion of carnitine, however, and 
can therefore not explain the initial drop in the plasma carnitine concentrations of valproate-
treated subjects. 
The most likely explanations for this initial drop are therefore an increased uptake of 
carnitine by tissues (skeletal muscle) and/or decreased carnitine biosynthesis. Increased 
uptake by tissues can be expected to be self-limiting, since export from tissues (either by 
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diffusion or transport proteins) must also increase when a new steady state is reached. Our 
observation that urinary excretion of carnitine and acylcarnitines remains low also during 
long-term treatment with valproate argues therefore against this possibility. The most likely 
reason for the initial drop in the plasma carnitine concentration is therefore a decrease in 
carnitine biosynthesis. This hypothesis is supported by our observation that the urinary 
excretion of butyrobetaine, the direct biosynthetic precursor of carnitine, also decreased 
sharply after starting valproate and remained low during long-term treatment with this drug. 
Farkas et al. have reported a decrease in carnitine biosynthesis in rats treated with 
valproate (Farkas et al., 1996) and have suggested an impaired conversion of 
butyrobetaine to carnitine as a possible mechanism. The data obtained in our patients 
argue against this mechanism, which should be associated with an increase in the 
butyrobetaine plasma concentration and also in its urinary excretion. Our data, which 
showed a decrease in renal excretion of butyrobetaine, favor an impact on carnitine 
biosynthesis proximal to the conversion of butyrobetaine to carnitine. In this context it is 
interesting to note that children have been reported to have a lower carnitine biosynthesis 
than adults (Rebouche et al., 1986), possibly explaining why children treated with valproate 
are more susceptible to hypocarnitinemia than adults. 
As shown in the current study and in the study of Stadler et al. (Stadler et al., 1999), 
subjects treated with valproate develop mechanisms to maintain their plasma carnitine 
concentrations after an initial drop. The most likely mechanism is an increased renal 
reabsorption of carnitine and short-chain acylcarnitines, which is supported by the current 
study and the study of Stadler et al. (Stadler et al., 1999). In patients with long-term 
valproate treatment, we observed a decrease in the excretion fractions of carnitine, 
acetylcarnitine, propionylcarnitine, and butyrobetaine, which are all transported by OCTN2 
(Todesco et al., 2008), the high affinity carnitine transporter responsible for the renal 
reabsorption of carnitine (Nezu et al., 1999; Stieger et al., 1995; Tamai et al., 1998). These 
observations suggest an increase in renal expression of OCTN2 in subjects treated with 
valproate, which could possibly be triggered by the initial drop in the plasma carnitine 
concentration. This hypothesis is supported by observations in vegetarians. Vegetarians 
have not only lower carnitine plasma concentrations compared to omnivores, but also a 
lower renal carnitine clearance (Lombard et al., 1989). Further support comes from a recent 
study in which we could show that rats with pharmacologically induced hypocarnitinemia 
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have an increased renal OCTN2 expression and transport of carnitine into proximal tubular 
brush border membrane vesicles (Schurch et al., 2010). 
Another mechanism by which OCTN2 could be upregulated is by the activation of PPAR, 
which is known to be involved in the regulation of OCTN2 expression in liver and intestine 
(Maeda et al., 2008; Ringseis et al., 2007). Since fatty acids and fatty acid derivatives are 
known activators of PPAR (Hawkins et al., 1987) valproate and/or valproylcarnitine could 
have similar properties taking into account their fatty acid structure. Moreover, older studies 
have demonstrated hepatic peroxisomal proliferation in rodents treated with valproate 
(Horie et al., 1985), indicating that valproate stimulates the PPAR signaling pathway. In 
human embryonic kidney cells, we observed an approximately 20% increase in the mRNA 
expression of OCTN2 after 24 to 48 h of incubation with 100 µmol/L valproate, but not in the 
presence of 5 µmol/L valproylcarnitine. Since we observed no effect of valproate or 
valproylcarnitine on the OCTN2 protein content, it appears unlikely, however, that this 
increase in mRNA expression is functionally relevant. The initial drop in the carnitine 
plasma concentration is therefore a more probable trigger of the suspected increase of the 
renal expression and function of OCTN2 in valproate-treated patients. 
In contrast to carnitine, acetylcarnitine and propionylcarnitine, the excreted fraction of the 
filtered valproylcarnitine approximated 100% in patients with long-term valproate treatment, 
indicating that valproylcarnitine is hardly reabsorbed by OCTN2. This finding could be 
confirmed by our in vitro studies with L6 cells overexpressing hOCTN2. Valproylcarnitine 
was transported by OCTN2, but only with a low affinity (Km 218 mol/L). This affinity is 
comparable to the affinity of pivaloylcarnitine to OCTN2, another drug metabolite studied in 
the same transport system (Todesco et al., 2009). The transport of valproylcarnitine was 
inhibited by carnitine (Ki 12.5 mol/L), suggesting that this inhibition is important under 
in vivo conditions. Taking into account the low plasma concentration (median 20 nmol/L) in 
comparison to the low affinity of valproylcarnitine to OCTN2 (Km 218 mol/L) and the 
expectable competition with carnitine for OCTN2, the renal reabsorption of valproylcarnitine 
could be predicted to be negligible. Similar conclusions have been reached by Ohnishi et al. 
who studied the transport of carnitine and valproylcarnitine in perfused rat kidneys and in 
cells expressing hOCTN2 (Ohnishi et al., 2008). Interestingly, in perfused rat kidneys, the 
reabsorption of valproylcarnitine was almost as efficient as for carnitine (Ohnishi et al., 
2008), suggesting species differences in the interaction of valproylcarnitine with OCTN2. 
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The plasma concentrations of valproylcarnitine (median 20 nmol/L) are far from its inhibitory 
constant for the transport of carnitine (Ki 80 mol/L), suggesting that any inhibitory effect of 
valproylcarnitine on the reabsorption of carnitine would be marginal. Accordingly, patients 
treated with valproate did not have significantly higher clearances or excretion fractions of 
carnitine and short-chain acylcarnitines compared to controls in our study. The data 
obtained in vitro are therefore in full agreement with the renal handling of carnitine and 
acylcarnitines in patients on long-term valproate treatment. 
5.6. Conclusions 
The current study shows that treatment with valproate does affect carnitine homeostasis. At 
the beginning of a therapy with valproate, patients develop hypocarnitinemia most probably 
due to an impairment of proximal steps of carnitine biosynthesis. During long-term 
treatment, the plasma carnitine levels normalize in most patients due to a higher renal 
reabsorption of carnitine and short-chain acylcarnitines. The plasma concentration of 
valproylcarnitine is too low to affect the reabsorption of carnitine and acylcarnitines at the 
level of OCTN2. 
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6.1. Summary 
Carnitine is an amino acid derivative that plays a key role in energy metabolism. 
Endogenous carnitine is found in its free form or bound to acyl groups of several chain 
lengths. Quantification of carnitine and acylcarnitines is of interest for the newborn 
screening of metabolic disorders and for the monitoring of patients at risk for 
hypocarnitinemia. 
We developed a method with online solid phase extraction coupled to high performance 
liquid chromatography and tandem mass spectrometry to quantify carnitine, acetylcarnitine, 
octanoylcarnitine, and palmitoylcarnitine, three acylcarnitines with different polarity. Plasma 
samples were deproteinized with methanol and loaded on a cation exchange trapping 
column. The analytes were separated on a reversed-phase C8 column using 
heptafluorobutyric acid as ion pairing reagent. Because of the endogenous nature of the 
analytes, we applied the addition method for their quantification. By adding known 
concentrations of carnitine, acetylcarnitine, octanoylcarnitine, and palmitoylcarnitine to 
plasma aliquots, we generated a standard curve with an intercept corresponding to the 
endogenous concentration. We determined the accuracy and precision of the method as 
well as stability and recovery of the analytes. Results were compared with an established 
radioenzymatic assay. 
We report a method for simultaneous quantification of carnitine and three acylcarnitines 
with an easy sample workup. This approach requires small sample volumes and short 
analysis time, providing a useful tool for clinical routine analysis. 
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6.2. Introduction 
Carnitine is an endogenous compound that plays a crucial role in energy metabolism. 
Carnitine is essential for the transport of long-chain fatty acids into the mitochondrial matrix 
for subsequent -oxidation (Fritz, 1955) and for the regulation of coenzyme A (CoA) and 
acyl-CoA pools (Brass et al., 1980; Friolet et al., 1994). These functions of carnitine involve 
the acylation of its -hydroxy group, leading to the formation of various acylcarnitines with 
different chain lengths (Steiber et al., 2004)(Figure 1). 
 
 
 
 
 
 
 
 
Figure 1: Structure of L-carnitine and three acyl-L-carnitines of different chain lengths 
 
 
Analytical profiling of carnitine and its acyl-derivatives is used to screen newborns and 
children for metabolic disorders or to monitor patients at risk or with established 
hypocarnitinemia (Millington et al., 1990). The traditional methods for the quantification of 
carnitine and acylcarnitines in plasma use HPLC separation coupled to MS/MS detection. 
The sample preparation can consist of several steps such as solid phase extraction (Vernez 
et al., 2003; Vernez et al., 2004) and esterification of carnitine and acylcarnitines at their 
carboxyl groups with different alcohols to enhance sensitivity (Chace et al., 1997; Minkler et 
al., 2008). Sample processing is time-consuming and imprecisions can arise from 
incomplete derivatization and/or hydrolysis of acylcarnitines during the derivatization 
process (Johnson, 1999). 
O-
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Because of the endogenous nature of carnitine and acylcarnitines, their quantification is 
mainly achieved with surrogate matrices such as dialyzed plasma or an albumin solution 
(Vernez et al., 2004), or with surrogate analytes (e.g. deuterated compounds) (Liu et al., 
2008; Longo et al., 1996; Minkler et al., 2008). Both approaches use substitute parameters 
for the original matrix or analyte so that comparative studies are required to ensure the 
validity of the model (Chau et al., 2008). 
For the analysis of clinical samples, both time and precision are important factors. Our aim 
was therefore to improve our existing method for plasma carnitine and acylcarnitine 
analysis (Vernez et al., 2004) by minimizing the time used for sample preparation and by 
optimizing the quantification procedure. We report a rapid and precise method for the 
simultaneous quantification of carnitine, acetylcarnitine, octanoylcarnitine, and 
palmitoylcarnitine in plasma samples using online solid phase extraction. To minimize 
matrix effects the addition method was used to quantify these endogenous analytes. 
6.3. Materials and Methods 
Reagents 
L-Carnitine, L-acetylcarnitine, and D,L-palmitoylcarnitine were purchased from Sigma (St. 
Louis, MO, USA). L-Octanoylcarnitine was obtained from Dr. H. J. ten Brink (VU Medical 
Center, Amsterdam, The Netherlands). L-Carnitine-d3, L-acetylcarnitine-d3, L-
octanoylcarnitine-d3, and L-palmitoylcarnitine-d3 were supplied by Cambridge Isotope 
Laboratories (Andover, MA, USA). 
All other chemicals and solvents were from Merck (Darmstadt, Germany) or Sigma and 
were of analytical grade. 
LC/MS-MS Equipment 
The HPLC system consisted of a HTS PAL autosampler (CTC Analytics AG, Zwingen, 
Switzerland), a column-oven (CTO-20A), four pumps (LC-20AD) and a controller (CBM-
20A) from Shimadzu (Reinach, Switzerland). The HPLC system was coupled to an API4000 
triple quadrupole mass spectrometer from AB/MDS Sciex (Concord, Canada) with an 
electron spray ionization source. 
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Samples were loaded on an Oasis MCX column (30 m, 2.1 x 20 mm; Waters Corporation, 
Milford, MA, USA) and separated on a Luna C8 5 m column (150mm x 2mm) equipped 
with a C8 precolumn (4 x 2.0 mm, Phenomenex, Torrance, CA, USA). 
Sample preparation and carnitine determination by LC/MS-MS 
Blood samples from seven healthy volunteers were collected in tubes containing lithium 
heparin. Plasma was obtained after centrifugation at 1’811 g for 10 minutes and stored at 
-20°C until analysis. For the determination of total carnitine, acylcarnitines were hydrolyzed 
under alkaline conditions. 25 L of sample were mixed with 25 L KOH 0.5 M (pH 13) and 
incubated at 40°C for 30 minutes. The mixture was then neutralized with 50 L 1% formic 
acid in water (V:V) and centrifuged for 10 minutes at 1’811 g. 
The plasma or hydrolyzed plasma sample to be analyzed was divided in five aliquots of 
10 L. To each of the 10 L aliquots, 0 to 40 L of aqueous standard solution was added in 
10 L steps. The missing standard solution volume in lower concentrations was 
compensated with the corresponding volume of water. The final concentrations in the 
standard solutions were as follows: carnitine 10-40 mol/L, acetylcarnitine 2.5-10 mol/L, 
octanoylcarnitine 0.02-0.08 mol/L, and palmitoylcarnitine 0.1-0.4 mol/L. The plasma 
samples were then deproteinized with the addition of 200 L of methanol containing the 
internal standards. The end concentrations of the internal standards were the following: 
carnitine-d3 20 mol/L, acetylcarnitine-d3 5 mol/L, octanoylcarnitine 0.04 mol/L, and 
palmitoylcarnitine 0.2 mol/L. The samples were mixed for 15 minutes at full speed on a 
Multi-tube Vortexer (VX-2500, VWR International) and centrifuged at 3’220 g for 30 
minutes. 
Quantification was made using the standard addition method. For this the plasma sample to 
be analyzed was divided into 5 aliquots of 10 L. One aliquot served as “blank” (no addition 
of exogenous carnitine and acylcarnitines) and four as standards (addition of carnitine and 
acylcarnitine standards at increasing concentrations). For total carnitine, aliquots of the 
hydrolyzed plasma after neutralization and centrifugation were used.  
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HPLC Conditions 
The chromatographic separation was done with a binary flow at 50°C. Phase A was an 
aqueous solution of 10 mmol/L of heptafluorobutyric acid and 10 mmol/L of ammonium 
acetate; phase B was methanol with the same additives. During 1.5 minutes, the analytes 
were loaded on the trapping column using 0.1% formic acid in water (V:V) as mobile phase 
(flow 0.5-1.0 mL/min), while the analytical column was conditioned with 10% phase B (flow 
0.35 mL/min). After valve switching, the analytes were transferred to the analytical column 
starting at 10% phase B with a linear increase of the gradient to 95% phase B within 4 
minutes. After a plateau of 2 minutes at 95% phase B, the analytical column was re-
equilibrated for 2 minutes with 10% B, resulting in a total run time of 8 minutes (Figure 2). 
 
 
 
Time  
[min] 
Flow 
[mL/min] 
Running 
buffers 
B concentration 
[%] 
Valve position 
0 0.5 Water  
+ 0.1% FA 
 Loading (A) 
1.5 1.0 
 
2 
0.35 
Water/MeOH  
+ 10 mmol/L HFBA 
+ 10 mmol/L AmAc 
10 
Elution (B) 
2.1 50 
4 95 
6 95 
8 10 
 
 
Figure 2: Valve switching configuration and chromatographic conditions. A: Valve is in the loading position. B: 
Valve is in the elution position. FA: formic acid; MeOH: methanol; HFBA: heptafluorobutyric acid; AmAc: 
ammonium acetate. 
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MS conditions 
Carnitine and the acylcarnitines of interest were analyzed in the multiple reaction monitoring 
mode. A first transition was used for quantification, a second one for qualification. Following 
positive mode transitions (m/z) were used: carnitine 162/103 and 162/60, carnitine-d3 
165/103 and 165/63, acetylcarnitine 204/85 and 204/145, acetylcarnitine-d3 207/85 and 
207/145, octanoylcarnitine 288/85 and 288/229, octanoylcarnitine-d3 291/85 and 291/229, 
palmitoylcarnitine 400/85 and 400/341, and palmitoylcarnitine-d3 403/85 and 403/341, 
respectively. 
The ion spray voltage was 5’500 eV, the probe temperature 450°C, and the dwell time 
50 ms for each analyte. 
Quantification with the standard addition method 
The quantification of carnitine, acetylcarnitine, octanoylcarnitine, and palmitoylcarnitine was 
achieved with the standard addition method. As described above, known amounts of the 
analytes were added to the plasma samples and a standard curve with an equation of the 
type baxy   was generated. The endogenous concentration was calculated as the 
intercept of the standard curve on the y-axis, defined as 
a
b
x

 . 
Qualification of the method 
We determined the accuracy and precision of the method as well as the stability and 
recovery of the analytes. Because of the endogenous nature of carnitine and its derivatives 
and the lack of blank plasma, we used spiked plasma samples for the determination of the 
accuracy. Pooled plasma was spiked with three concentrations of carnitine, acetylcarnitine, 
octanoylcarnitine, and palmitoylcarnitine (low, medium and high quality controls, QC), 
containing the unknown endogenous concentration of the pooled plasma plus 12.5, 25, 
37.5 mol/L carnitine, 3, 6, 9 mol/L acetylcarnitine, 0.03, 0.06, 0.09 mol/L 
octanoylcarnitine, and 0.125, 0.25, 0.375 mol/L palmitoylcarnitine, respectively. 
For free carnitine and total carnitine, the results obtained with our method were compared 
with the results obtained with a radioenzymatic assay originally described by Cederblad & 
Lindstedt (Cederblad et al., 1972) and modified by Brass and Hoppel (Brass et al., 1978). 
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Recovery was assessed with three concentrations of the four analytes spiked before or 
after the protein precipitation step. For the assessment of short-term stability, samples were 
spiked, stored at room temperature for 8h, analyzed and compared to freshly spiked 
samples. For stability under storage conditions, samples were spiked and kept frozen at 
-20°C for one week. The samples were then analyzed and compared to freshly spiked 
plasma samples. For freeze/thaw stability, freshly prepared samples were frozen at -20°C 
for at least 12h and then thawed at room temperature for 30 minutes. After three 
freeze/thaw cycles, the samples were analyzed and compared to freshly prepared samples. 
To determine the stability of the analytes in solution, freshly made stock solutions were 
analyzed and compared to stock solutions that had been stored at -20°C for four months. 
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6.4. Results 
Method qualification 
We first tested the feasibility of a classical quantification with standard curves prepared in 
carnitine-free matrices such as water or 4% bovine serum albumin (BSA). Since the slopes 
of the standard curves in water containing BSA were different from the slopes in pooled 
plasma for carnitine and acetylcarnitine (Figure 3A-D), we applied the addition method to 
account for the observed matrix effects. 
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Figure 3: Standard curves of carnitine (A), acetylcarnitine (B), octanoylcarnitine (C) and palmitoylcarnitine (D) 
generated in water (■), BSA 4% (▲) or pooled plasma (●). Different slopes for carnitine and acetylcarnitine in 
plasma prompted us to use the addition method for quantification to account for matrix effects. For pooled 
plasma, the endogenous concentration was subtracted for clarity. Concentrations are given in mol/L. 
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The mean recoveries of carnitine, acetylcarnitine, octanoylcarnitine, and palmitoylcarnitine 
for three different concentrations are reported in Table 1. The analytes, added to pooled 
plasma, were stable after three freeze-thaw cycles. After one week at -20°C, acetylcarnitine 
and octanoylcarnitine showed a drop by 7.4% and 11.4%, respectively. Similarly, after 8h at 
room temperature, acetylcarnitine and octanoylcarnitine had decreased by 5.9 and 6.4%, 
respectively, while carnitine and palmitoylcarnitine remained stable (Table 1). 
 
 Recovery 
Freeze-thaw 
stability 
1 week 
stability 
8h stability 
Stability of 
stock 
solution 
Carnitine 100.6±0.7% 103.2±1.5% 95.2±4.1% 103.1±5.5% 99.0±16.3% 
Acetylcarnitine 98.4±2.7% 105.3±2.7% 92.6±3.7% 94.1±2.3% 102.8±16.5% 
Octanoylcarnitine 102.3±3.8% 103.7±3.7% 89.6±7.1% 93.6±2.9% 110.0±24.9% 
Palmitoylcarnitine 105.6±2.2% 103.6±4.1% 95.8±1.2% 98.7±6.3% 99.2±27.8% 
 
Table 1: Recovery and stability. Stability studies of the four analytes were performed on seven replicates of 
the three quality controls. 
 
Accuracy was assessed with three quality controls measured on three different days. The 
QCs were generated from pooled plasma spiked with three known concentrations of the 
four analytes. The target values were calculated by adding the determined concentration of 
the pooled plasma to the spiked concentrations. For total carnitine, carnitine, and 
acetylcarnitine, the measured concentrations were within ± 7.5% of the expected 
concentrations. For octanoylcarnitine and palmitoylcarnitine, the variability was higher, 
exceeding 20% for the low octanoylcarnitine QC (Table 2). 
Precision was determined from plasma samples of seven healthy volunteers, one pooled 
plasma sample and three quality controls at different concentrations (low, medium and 
high). The samples were analyzed with the addition method on three different days. For 
free carnitine, acetylcarnitine, and total carnitine, the interday coefficients of variation (CV) 
did not exceed 10%. For low concentrations of octanoylcarnitine and palmitoylcarnitine we 
observed a higher variability with interday CVs up to 28% (Table 3). 
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  Low QC Medium QC High QC 
Free carnitine Expected 62.1 74.6 87.1 
 Measured 59.6 74.2 88.3 
 Accuracy 96.0% 99.5% 101.4% 
Acetylcarnitine Expected 8.5 11.5 14.5 
 Measured 8.6 11.1 13.9 
 Accuracy 101.5% 97.0% 96.0% 
Octanoylcarnitine Expected 0.10 0.13 0.16 
 Measured 0.13 0.12 0.13 
 Accuracy 126.8% 93.0% 81.1% 
Palmitoylcarnitine Expected 0.29 0.41 0.54 
 Measured 0.34 0.39 0.64 
 Accuracy 119.5% 93.3% 118.2% 
Total carnitine Expected 81.9 97.6 113.2 
 Measured 80.3 90.3 111.4 
 Accuracy 98.0% 92.5% 98.4% 
 
 
Table 2: Accuracy. Accuracy was assessed with three quality controls (low, medium, high) generated from 
pooled plasma spiked with three different concentrations of carnitine and three acylcarnitines. The expected 
concentration was calculated from the concentration measured in pooled plasma plus the spiked 
concentrations. Concentrations are given in mol/L. 
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 Free carnitine Acetyl-
carnitine 
Octanoyl-
carnitine 
Palmitoyl-
carnitine 
Total carnitine 
 mean CV% mean CV% mean CV% Mean CV% mean CV% 
Subject 1 54.4 4.8 6.8 7.3 0.07 16.3 0.15 16.0 71.7 13.8 
Subject 2 52.3 9.6 5.9 7.7 0.06 14.7 0.13 11.9 64.2 5.8 
Subject 3 44.5 2.1 4.5 2.7 0.10 13.9 0.12 12.0 57.5 1.7 
Subject 4 58.1 6.2 5.0 5.6 0.06 12.9 0.18 13.6 72.5 9.1 
Subject 5 46.5 9.6 4.6 8.6 0.05 27.4 0.11 9.9 61.2 10.4 
Subject 6 60.0 9.5 6.5 7.0 0.07 12.1 0.14 15.2 71.5 14.5 
Subject 7 45.9 8.1 8.0 7.0 0.11 8.7 0.17 26.7 57.4 3.4 
Pooled 49.6 8.8 5.5 7.8 0.07 6.9 0.16 10.0 66.3 13.5 
QC L 59.6 8.1 8.6 4.5 0.13 9.37 0.34 16.9 80.3 8.4 
QC M 74.2 10.0 11.1 6.8 0.12 16.11 0.39 21.4 90.3 16.9 
QC H 88.3 1.3 13.9 7.1 0.13 5.70 0.64 7.80 111.4 7.9 
 
 
Table 3: Precision. The precision of the method was evaluated with repetitive measurements (n=3) of seven 
plasma samples, one pooled plasma sample and three quality controls. Concentrations are given in mol/L. 
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Cross-comparison of plasma samples from seven healthy volunteers was performed with 
an established radioenzymatic method. The two methods provided comparable values with 
a correlation of 0.93 for free carnitine and a correlation of 0.92 for total carnitine (Figure 4). 
For free carnitine, we observed a mean systematic shift of 7 mol/L between our method 
and the radioenzymatic assay. The difference exceeded 15% for only one sample. 
 
Figure 4: Carnitine (■) and total carnitine (○) concentrations were measured with the developed method (LC-
MS/MS) and with an established radioenzymatic assay (REA). The two methods were compared using linear 
regression (A, C) and Bland-Altman plots (B, D). Concentrations are given in mol/L. 
 
Application of the method 
The method was applied for the quantification of carnitine and three acylcarnitines in 
plasma samples of one healthy volunteer completing a cycling exercise until exhaustion. As 
expected, we observed increasing acetylcarnitine concentrations with increasing effort 
(Figure 5A). Carnitine concentrations slightly decreased (Figure 5A) while octanoylcarnitine and 
palmitoylcarnitine concentrations were not affected by exercise (Figure 5B). 
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Figure 5: The new method was applied for the quantification of carnitine and acylcarnitines in plasma 
samples of one healthy volunteer completing a cycle exercise with increasing work load until exhaustion. The 
workload (bars) started at 220 W and was increased by 20 W every 2 min. Exhaustion was reached after 18 
min at 380 W. A: Carnitine (■) and acetylcarnitine (▲), B: octanoylcarnitine (●) and palmitoylcarnitine (♦). 
Mean concentration in mol/L ±SD of 3 determinations are shown. 
 
6.5. Discussion 
We have developed a fast and simple method for the determination of carnitine and three of 
its acyl derivatives in human plasma. The method is based on protein precipitation and 
online solid phase extraction followed by direct determination of the analytes by LC-MS/MS. 
The analytes in the reported method cover a wide range of lipophilicity – from the small and 
polar carnitine to the lipophilic palmitoylcarnitine – and would be applicable to other 
acylcarnitines in this solubility range. The small sample volume needed – 75 L for the 
determination of acylcarnitine profile and total carnitine – is advantageous for situations 
where only small blood volumes are available, as for instance in pediatric patients. 
Solid phase extraction (SPE) is widely used during sample preparation for the 
determination of carnitine and acylcarnitines (Minkler et al., 2008; Vernez et al., 2004). 
Since carnitine is a cation under acidic conditions, cation exchangers are the preferred 
matrices to optimize retention (Vernez et al., 2004). Solid phase extraction can enhance the 
sensitivity of the chromatographic assays, but the process can be time-consuming when 
operated off-line. In comparison, online solid phase extraction coupled to chromatographic 
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separation in one run conciliates the advantages of SPE with time efficiency. This is 
demonstrated with our method, enabling solid phase extraction and sample analysis within 
8 minutes. 
Derivatization is common for the analysis of acylcarnitines, with the advantages of 
increasing the sensitivity and optimizing the chromatographic properties of the analytes 
while prolonging sample preparation. On the other hand, disadvantages of derivatization 
include incomplete reaction, possible degradation of the analytes and prolongation of the 
sample work-up. We therefore prefer methods without derivatization for the reasons 
previously described (Vernez et al., 2003; Vernez et al., 2004). 
Quantification of carnitine and acylcarnitines is complicated by the endogenous nature of 
the analytes. Classical quantification with standard curves in a blank matrix as used for 
exogenous compounds can only be achieved with denatured matrices such as dialyzed 
plasma (Liu et al., 2008; Vernez et al., 2004). An alternative are albumin-containing 
solutions, which have been used for the radioenzymatic method (Brass et al., 1978) or also 
for LC/MS methods (Vernez et al., 2004). In the current study, standards in water or in 
albumin-containing solutions had a substantially different slope compared to standards in 
plasma, precluding their use as a matrix for standards. One possible solution of this 
problem is the above-mentioned pre-treatment of plasma, but procedures such as dialysis 
are time consuming. The addition method, which allows the quantification of the analytes in 
native matrix, avoids artifacts of surrogate or denatured matrices by directly accounting for 
matrix effects. A possible disadvantage of this method is the fact that a single sample has 
to be analyzed several times in order to obtain a reliable curve which can be used for 
quantification. Taking into account the short analysis time, this disadvantage is acceptable. 
Besides, the same standard solution in different volumes is added to the plasma aliquots, 
enabling a semi-automated sample processing within 5 minutes. Together with the 30 
minutes hydrolysis time for the determination of total carnitine, mixing and centrifugation 
steps, reliable quantification of total carnitine, free carnitine and acylcarnitines can be 
achieved within half a day. Our method consists of a rapid and simple procedure in 
comparison to published methods using derivatization times of typically 15 minutes, 
hydrolysis times of one hour for total carnitine, LC runs of 30 minutes or more (Maeda et al., 
2007; Minkler et al., 2008; Sun et al., 2006), or potential evaporation and reconstitution 
steps. 
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In terms of precision, our method shows comparable results as described in the literature 
(Ghoshal et al., 2005; Minkler et al., 2008). Coefficients of variation were below 10% for 
carnitine and acetylcarnitine and below 15% for total carnitine. We observed higher 
variability for octanoylcarnitine and palmitoylcarnitine, remaining nevertheless within 
acceptable limits, considering the mean variation obtained for all plasma samples and 
considering the low concentrations measured. For palmitoylcarnitine, similar interday 
precisions have been reported by Ghoshal and colleagues (13.7%) and Minkler and 
colleagues (0.11±0.02, corresponding to a CV of 18%) (Ghoshal et al., 2005; Minkler et al., 
2008). 
Regarding the sensitivity of our method, we defined the lower limits of quantification (LLOQ) 
for octanoylcarnitine and palmitoylcarnitine with the lowest QC measured with reliable 
precision and accuracy, in order to avoid a surrogate matrix or matrix dilution. For 
octanoylcarnitine, the LLOQ was 0.03 mol/L and for palmitoylcarnitine 0.125 mol/L. 
 
We describe a fast and reliable method for the quantification of carnitine and three 
acylcarnitines requiring small sample volumes and short total analysis time. This simple 
approach with minimal sample workup represents a useful method for clinical analysis. 
  70 
7. EFFECTS OF CARNITINE, ACETYLCARNITINE AND PROPIONYLCARNITINE 
SUPPLEMENTATION ON SKELETAL MUSCLE PARAMETERS AND PHYSICAL 
PERFORMANCE OF MICE 
 
Réjane Morand, Jamal Bouitbir, Andrea Felser, and Stephan Krähenbühl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Pharmacology & Toxicology, University Hospital Basel and Department of Biomedicine, 
University of Basel, Switzerland 
 
  71 
7.1. Abstract 
Carnitine is a zwitterionic molecule with key functions in energy metabolism. Whereas most 
studies failed to show an accumulation of carnitine in skeletal muscle while supplementing 
carnitine, the effects of high oral doses of acetylcarnitine or propionylcarnitine on skeletal 
muscle composition and function are unknown. We therefore investigated the effects of 
carnitine, acetylcarnitine and propionylcarnitine supplementation on body carnitine 
homeostasis and skeletal muscle capacity of mice. Animals were supplemented with 
2 mmol/kg/d carnitine, acetylcarnitine or propionylcarnitine via drinking water for four 
weeks. After this period, half of the mice were submitted to an exhaustive treadmill exercise 
while the other half served as control group. We determined endurance parameters, 
carnitine and acylcarnitines concentrations in muscle, plasma and urine of supplemented 
animals compared to a control group not treated with carnitine. In soleus and in 
gastrocnemius muscle biopsies, we investigated the muscular oxidative capacity in 
presence of specific mitochondrial substrates. Energy parameters such as lactate in 
plasma, phosphocreatine, creatine and glycogen in white and red portions of the 
quadriceps femoris muscle were determined. 
In the supplemented groups, the total carnitine concentrations in plasma and in urine were 
significantly higher than in controls groups, whereas we observed no difference in muscle 
carnitine content. The bioavailability of supplemented carnitine or acylcarnitines, estimated 
as the difference between carnitine supplementation and urinary excretion, was in the 
range of 20 to 23%. The supplemented acylcarnitines were hydrolyzed before reaching the 
systemic circulation. The ex vivo oxygen consumption by isolated muscle fibers from soleus 
or gastrocnemius was not different between supplemented and control mice. The 
supplementation of carnitine or acylcarnitines had no influence on the running capacity of 
the animals or key substrates of energy metabolism. 
In conclusion, oral supplementation of carnitine, acetylcarnitine or propionylcarnitine was 
associated with increased plasma concentrations of total carnitine and increased urinary 
excretion of carnitine, but did not affect the skeletal muscle carnitine content. Accordingly, 
physical performance and skeletal muscle energy metabolism were not significantly 
affected by carnitine supplementation. 
  72 
7.2. Introduction 
Carnitine is an amino acid derivative which plays an essential role in cellular energy 
metabolism due to acylation of its -hydroxy group. The main body carnitine pool is in 
skeletal muscle (Krahenbuhl et al., 2000; Spaniol et al., 2001), where carnitine functions as 
carrier of long chain-fatty acids (Fritz, 1955) and as a regulator of the CoASH/acetyl-CoA 
ratio (Brass et al., 1980; Friolet et al., 1994). 
Carnitine is an obligatory intermediate for the transport of long chain fatty acids into the 
mitochondria. In order to reach the mitochondrial matrix for subsequent -oxidation, long 
chain fatty acids have first to be converted into the corresponding acyl-CoA and then into 
the acylcarnitine derivative. The second step is achieved by carnitine palmitoyltransferase 1 
(CPT 1), the rate limiting enzyme of β-oxidation (Roepstorff et al., 2005). As acylcarnitines, 
long-chain fatty acids are transported across the inner mitochondrial membrane through the 
carnitine/acylcarnitine carrier (Indiveri et al., 2011) into the mitochondrial matrix, where they 
enter the -oxidation cycle after reconversion into the acyl-CoA derivative by CPT2 
(Bremer, 1983). 
During high intensity exercise, acetyl-CoA generated by pyruvate oxidation or -oxidation 
overwhelms the capacity of the Krebs cycle. The limited CoA pool would rapidly be 
depleted by the accumulating acetyl-CoA, if carnitine could not function as a buffer for the 
acetyl groups. Carnitine acetyltransferase converts acetyl-CoA to acetylcarnitine, thereby 
ensuring the availability of free coenzyme A (CoASH) (Brass et al., 1980; Friolet et al., 
1994). 
Taking into account these important functions of carnitine, it is not surprising that carnitine 
supplementation has been studied intensively as a potential performance enhancer (Brass, 
2004). In ex vivo models it has been reported that an elevation of the carnitine muscle 
content increases skeletal muscle force and delays fatigue (Brass et al., 1993; Dubelaar et 
al., 1991). In humans, most studies failed to show a positive effect of carnitine 
supplementation on physical performance, correlating with the fact that the muscle carnitine 
content could not be increased by oral or parenteral means despite elevated plasma 
concentrations (Brass, 2000). High oral doses of carnitine during several days or 
intravenous infusion for several hours before exercise failed to show an impact on the 
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physical performance of healthy volunteers or athletes (Barnett et al., 1994; Oyono-
Enguelle et al., 1988; Wachter et al., 2002). Recently, Wall et al. reported an approximately 
20% increase of the carnitine muscle content in human subjects ingesting 80 g 
carbohydrate per day and oral carnitine intake (Wall et al., 2011). This increase in the 
skeletal muscle carnitine content was associated with an increase in work output, 
maintained skeletal muscle glycogen stores and a reduced production of lactate. 
In rodents, studies investigating the accumulation of carnitine in skeletal muscle associated 
with carnitine supplementation are controversial. An increase of the skeletal muscle 
carnitine content of supplemented animals was reported by several groups (Bacurau et al., 
2003; Negrao et al., 1987), while in other investigations, no such increase could be 
detected (Lambert et al., 2009; Primassin et al., 2008). 
Whereas the dose und duration of carnitine supplementation seems to influence skeletal 
muscle carnitine accumulation in rodents, little is known about the effect of supplementation 
with carnitine derivatives, e.g. acetylcarnitine or propionylcarnitine, on the skeletal muscle 
carnitine content and physical performance. Elevated carnitine plasma concentrations are 
not necessarily associated with an increase in the skeletal muscle carnitine content due to 
saturation of the carnitine transport system into skeletal muscle at normal carnitine plasma 
concentrations (Berardi et al., 2000) and due to a large concentration gradient between 
plasma and skeletal muscle (Brass, 2000; Friolet et al., 1994). For acetylcarnitine and 
propionylcarnitine, concentrations differences between plasma and skeletal muscle are not 
as extreme, possibly also allowing passive diffusion as a transport mechanism. 
In this study we therefore aimed to investigate the potential benefits of acetylcarnitine or 
propionylcarnitine supplementation in comparison to carnitine on the muscular carnitine 
content and working capacity of mice. After oral supplementation during four weeks, mice 
were subjected to exhaustive exercise and the plasma and skeletal muscle carnitine pools 
as well as metabolic markers in muscle and plasma were analyzed. 
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7.3. Material and methods 
 
Animals 
The experiments were performed in agreement with the guidelines for the care and use of 
laboratory animals and were approved by the cantonal veterinary authority (License 2509). 
The animals were adult male C57BL/6 mice (Janvier, Le Genest-Saint-Isle, France), 
housed in a standard facility with a 12h:12h light-dark cycle. The mice were fed with a 
standard pellet chow and water ad libitum. Before starting supplementation, the animals 
were acclimatized to the animal facility for at least 7 days. 
Supplementation 
L-carnitine and acetyl-L-carnitine HCl were purchased from Sigma (St. Louis, MO, USA). 
Propionyl-L-carnitine HCl was a kind gift of Sigma Tau (Pomezia, Rome, Italy). 
The solutions of carnitine, acetylcarnitine and propionylcarnitine were made in tap water 
once a week and were kept at 4°C during that time. After one week of acclimatization, the 
mice were supplemented with carnitine (CN), acetylcarnitine (ACN) or propionylcarnitine 
(PCN) via drinking water during four weeks (4 groups, each group n=6). The concentration 
of the salts in tap water was 10 mmol/L so that mice of about 25 g drinking 5 mL/d would be 
exposed to approximately 2 mmol/kg/d of each compound. Water consumption was 
monitored daily. The carnitine content in the standard chow and in the drinking water was 
evaluated with a LC-MS/MS method previously described (Morand, 2012). 
Protocol 
Between week 1 and 2 of supplementation, the mice spent 24h in individual metabolic 
cages with supplemented water and food ad libitum. 24h urine was collected for the 
analysis of the excretion of carnitine and acylcarnitines. 
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After four weeks of supplementation, the mice were submitted to an exhaustive exercise on 
a treadmill with previous acclimatization to the apparatus (Exer-3/6, Columbus Instruments, 
Columbus, OH, USA). The starting speed was 5 m/min; after 5 minutes, the speed was 
increased by 1 m/min every minute until the maximal speed of 20 m/min was reached. 
Exhaustion was defined as immobility for more than 5 seconds on the end lane grid despite 
electric stimulation (0.4 mA, 2 Hz). 
Performance of the mice was calculated from the distance and the duration of the run 
according to the following equation: 
 
(1) (s) t
(m) d  )(m/s a  (kg) m
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2 
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Biological sample collection 
After exhaustion the mice were anaesthetized with an intraperitoneal application of 
ketamine (100 mg/kg) and xylazine (10 mg/kg). The soleus and gastrocnemius muscle 
were excised and conserved in ice cold BIOPS buffer (10 mmol/L Ca-EGTA buffer, 
0.1 mol/L free calcium, 5.77 mmol/L ATP, 6.56 mmol/L MgCl2, 20 mmol/L taurine, 
15 mmol/L phosphocreatine, 0.5 mmol/L dithiothreitol, and 50 mmol/L K-MES, pH 7.1) until 
analysis. Blood was collected into heparin coated tubes by an intracardiac puncture or a tail 
incision. Plasma was separated by centrifugation at 3000 g for 15 minutes. 
For chemical analysis muscle samples from the red and white quadriceps femoris were 
frozen in liquid nitrogen immediately after excision. Plasma, urine and muscle samples 
were kept at -80°C until analysis. 
  76 
High resolution respirometry 
All oxygen measurements were performed at 30°C with an Oxygraph 2k apparatus 
equipped with the Datlab software (OROBOROS, Innsbruck, Austria). Muscle biopsies 
preserved in BIOPS buffer were prepared according to an established protocol (Pesta et al., 
2012). Muscle fibers were permeabilized during 30 min in BIOPS buffer containing saponin 
(50 g/mL). Per respiration chamber, 1-2 mg of permeabilized fibers was added to 2.0 mL 
of MiR05 buffer (EGTA 0.5 mmol/L, MgCl2 3 mmol/L, taurine 20 mmol/L, KH2PO4 
10 mmol/L, HEPES 20 mmol/L, D-sucrose 110 mmol/L, BSA essentially fatty acid free 
1 g/L, and lactobionic acid 60 mmol/L). 
The following protocol was used to evaluate the activity of the different mitochondrial 
complexes: glutamate (10 mmol/L) and malate (2 mmol/L), ADP (2.5 mmol/L), rotenone 
(0.5 mol/L), succinate (10 mmol/L), malonate (20 mmol/L), antimycin A (2.5 mol/L), and 
TMPD/ascorbate (0.5/2 mmol/L). To verify the integrity of the outer mitochondrial 
membrane, cytochrome c (10 mol/L) was added at the end of the respiration protocol. 
Respiration rates are expressed in picomoles O2 per minute per gram wet weight. 
Urinary carnitine concentrations 
A LC-MS/MS method previously described was adapted for the determination of carnitine 
and acylcarnitines in urine (Morand, 2012). The method was extended to the analysis of 
propionylcarnitine (transitions 218/85 and 218/159) and creatinine (114/44 and 114/86). 
Hydrolysis of total carnitine was achieved with 0.5 mol/L potassium hydroxide, 
neutralization and dilution with 0.1% formic acid. 
Plasma parameters 
Plasma concentrations of carnitine were determined as previously described with 
adaptation to propionylcarnitine (Morand, 2012). Venous lactate concentrations were 
analyzed with an enzymatic assay (Olsen, 1971). Creatine kinase activity in venous plasma 
was determined before and after exhaustive exercise with a kit according to the supplier’s 
instructions (BioAssay Systems, Hayward, CA, USA). 
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Muscle parameters 
Muscle tissue was homogenized with a Mikro-dismembrator during 1 minute at 2000 rpm 
(Sartorius Stedim Biotech, Göttingen, Germany). 50 mg muscle was extracted with 1 mL of 
extracting solvent depending on the metabolites determined as described below. 
Phosphocreatine, creatine, and ATP were photometrically determined in an acidic extract 
(perchloric acid 0.5 mol/L, EDTA 1 mmol/L) of muscle powder as previously described 
(Harris et al., 1974). Muscle glycogen content was analyzed in alkaline (NaOH 0.1 mmol/L) 
muscle extracts according to Harris (Harris et al., 1974). Carnitine, acylcarnitines and total 
carnitine were determined in aqueous muscle extracts with an established LC-MS/MS 
(Morand, 2012). 
Statistical analysis 
Data is expressed as mean ± SEM. Statistical analyses were performed using Student’s 
t-test or one-way ANOVA with the software Prism version 5 (Graph Pad Software, San 
Diego, CA). Statistical significance was set at *p < 0.05 and **p < 0.01. 
7.4. Results 
Characterization of the animals 
During the study, we observed no weight differences between the groups (Figure 1A). Food 
intake was similar in all the groups. The daily water intake was increased in all treated 
groups compared to control group (Figure 1B). The control animals (n=12) drank 
4.1 ± 0.6 mL/d, whereas the animals of the carnitine (CN), acetylcarnitine (ACN), and 
propionylcarnitine (PCN) group ingested 5.2 ± 0.3 mL/d, 5.7 ± 0.9 mL/d, and 5.6 ± 0.4 mL/d, 
respectively (mean ± SD; no difference between treated animals). The mean daily exposure 
to exogenous carnitine, acetylcarnitine or propionylcarnitine was 2.2 mmol/d/kg 
(1.9-2.7 mmol/d/kg) in the treated groups and below 10 mol/kg/d in the control group, 
taking into account carnitine ingested by the drinking water and by food (Figure 1C). The 
carnitine content of the food was 60 nmol/g. The concentrations of carnitine, acetylcarnitine, 
and propionylcarnitine in the drinking solutions remained stable during their storage in the 
water bottles at room temperature (data not shown). 
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Figure 1: Characterization of the animals. The weight gain (in grams) was similar in the treatment groups 
compared to control (A). Water consumption (in mL/mouse/d) was significantly higher in the treated groups 
(B). Daily consumption of carnitine or acylcarnitines was below 10 mol/kg/d in the control group and in the 
range of 2000 mol/kg/d in the supplemented groups (C). Data is represented as mean ± SEM of 12 animals 
per group. 
 
Carnitine and acylcarnitine pools in plasma and skeletal muscle and renal carnitine 
excretion 
In plasma, total carnitine concentrations were significantly higher in the treated groups 
(Table 1), associated with higher free carnitine concentrations. Acetylcarnitine, 
propionylcarnitine, and palmitoylcarnitine plasma concentrations were similar between the 
groups. 
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In red or white quadriceps muscle, we observed no difference between the groups treated 
with carnitine or acylcarnitines and the control group. The acetylcarnitine concentrations 
accounted for 20% of the total pool in red fibers and for 15% in the white fibers. Total 
carnitine, free carnitine, acetylcarnitine, and palmitoylcarnitine concentrations were by trend 
lower in the white compared to red quadriceps. Propionylcarnitine concentrations in skeletal 
muscle were below detection limits, also in mice treated with propionylcarnitine (Table 1). 
 
 Control Carnitine ACN PCN 
Plasma concentrations (mol/L) 
Carnitine 31.0±0.5 37.2±2.2 36.1±1.4 35.6±3.4 
Acetylcarnitine 7.8±0.8 8.5±1.3 9.3±0.6 7.6±0.7 
Propionylcarnitine 0.30±0.04 0.24±0.07 0.27±0.04 0.76±0.38 
Palmitoylcarnitine 0.25±0.01 0.29±0.04 0.25±0.02 0.30±0.03 
Total carnitine 36.4±1.4 47.7±1.8** 47.6±1.6** 42.7±1.6* 
Skeletal muscle concentrations (mol/kg wet weight) 
Red quadriceps  
Free carnitine 205±29 272±32 216±25 189±14 
Acetylcarnitine 66±7 69±11 70±3 62±9 
Propionylcarnitine <0.5 <0.5 <0.5 <0.5 
Palmitoylcarnitine 44±8 55±6 32±12 28±5 
Total carnitine 291±31 309±59 359±56 249±43 
White quadriceps  
Free carnitine 110±7 115±10 127±11 130±11 
Acetylcarnitine 39±5 37±10 26±3 28±5 
Propionylcarnitine <0.5 <0.5 <0.5 <0.5 
Palmitoylcarnitine 15±5 20±3 14±3 19±5 
Total carnitine 195±17 207±14 169±20 152±14 
 
Table 1: Carnitine and acylcarnitines concentrations in plasma and skeletal muscle under resting conditions. 
Mean values ± SEM of six animals are represented. **: p<0.01 compared to control, * p<0.05 compared to 
control. ACN: Acetylcarnitine, PCN: Propionylcarnitine. 
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Treated animals excreted about 17 times more total carnitine than controls animals 
(24 ± 4 mol/kg/d in the control group vs. 417 ± 143, 390 ± 76, and 448 ± 36 mol/kg/d in 
the carnitine, ACN, and PCN treated groups respectively) (Table 2). The excreted carnitine 
was found principally in the form of free carnitine and acetylcarnitine (Figure 2). In all treated 
groups, independently of the supplemented form of carnitine, the excretion of 
acetylcarnitine was significantly higher (41 ± 10 mol/kg/d in the carnitine group, 54 ± 13 in 
the ACN group, and 46 ± 6 for the PCN group) compared to control animals 
(2 ± 0 mol/kg/d). Urinary excretion of propionylcarnitine could only be detected in the three 
treated groups, whereas the propionylcarnitine concentration was below the limit of 
detection in the urine of control mice. The highest urinary propionylcarnitine concentrations 
were found in the PCN group (3.3 ± 1.1 mol/kg/d vs 1.0 ± 0.3 mol/kg/d, and 
1.1 ± 0.3 mol/kg/d in the CN and ACN groups respectively). Due to the high variability, this 
difference did not reach statistical significance (Table 2). 
 
 
 
 
Figure 2: Mean urinary excretion of carnitine, acetylcarnitine, and total carnitine. Mice supplemented with 
carnitine, acetylcarnitine or propionylcarnitine excreted significantly higher amounts of carnitine and 
acetylcarnitine than the control group. Data is expressed as mol/kg/d (mean ± SEM of 6 animals per group). 
**: p<0.01 compared to control 
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 CTRL CARNITINE ACN PCN 
Free carnitine 19±2 356±71** 335±68** 360±34** 
Acetylcarnitine 2±0 41±10** 54±13** 46±6** 
Propionylcarnitine n.d. 1.0±0.3** 1.1±0.3** 3.3±1.1** 
Total carnitine 24±4 417±143** 390±76** 448±36** 
 
Table 2: Excretion of carnitine, acetylcarnitine, propionylcarnitine, and total carnitine. Excreted amounts are 
mean values ± SEM of 6 animals, given in mol/kg/d. **: p<0.01 compared to control group. 
 
 
Carnitine balance under resting conditions 
Total carnitine input and output in control and treated animals are presented in Table 3. The 
total intake of carnitine was 200 times higher in animals supplemented with carnitine, 
acetylcarnitine or propionylcarnitine. Excretion, as discussed above, was 10 to 20 times 
higher in the treated groups as compared to the control group. The tissue accumulation was 
calculated from the mean total carnitine concentration in red and white muscles and from 
the estimated muscle weight gain during the observation period of one month. The 
difference was calculated by subtracting the excretion plus tissue accumulation from total 
intake of carnitine. In control mice, the negative difference represents mainly carnitine 
biosynthesis. This value is in agreement with reported values in rats obtained by a similar 
method (Krahenbuhl et al., 2000). In treated animals, the positive value is mainly explained 
by incomplete bioavailability. Bioavailability, as estimated from carnitine ingestion and 
urinary excretion, was between 20% and 23% without a difference between the groups 
supplemented with carnitine or acylcarnitines. 
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Treatment group (n = 6) Intake Excretion 
Tissue 
accumulation Difference 
 Water Food    
Control 0±0 9.5±0.1 31±4 0.32±0.06 -22±4 
Carnitine 2072±27 9.6±0.2 472±152 0.40±0.10 1609±155 
Acetylcarnitine 2254±114 9.6±0.2 451±80 0.30±0.06 1812±140 
Propionylcarnitine 2259±48 9.6±0.2 501±40 0.44±0.08 1767±63 
 
Table 3: Total carnitine balance under resting conditions. The difference was calculated by subtracting the 
excreted and accumulated amounts from the intake. Values are given in mol/kg/d ± SEM. 
 
High resolution respirometry 
For the soleus and the gastrocnemius muscle biopsies, we observed no significant 
difference in oxygen uptake for the different conditions tested between the groups 
investigated. These findings suggest that mitochondrial content and capacity remained 
unchanged in the supplemented compared to the control group (Figure 3). As expected, the 
maximal respiration rate in the red soleus muscle was higher than in the white 
gastrocnemius. 
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Figure 3: Oxygen consumption by isolated muscle fibers. We observed no differences between 
supplemented mice and control mice. Data is represented as mean in pmol O2/s/mg wet weight ± SEM of six 
animals. 
 
Exercise 
As shown in Figure 4, the mean running distance of untreated mice was 561 ± 150 m (n=6). 
The distance covered by treated mice was by trend increased in all groups but no statistical 
significance was observed because of high interindividual variability (carnitine 699 ± 265 m, 
acetylcarnitine 772 ± 320 m, propionylcarnitine 820 m ± 525 m). The performance of the 
animals was in the range of 67 – 69 mW and did not differ between the groups. 
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Figure 4: Running capacity of mice completing a treadmill exercise until exhaustion. We observed a slight 
upward trend for the running distance (A) in treated groups. Performance expressed in mW (B) did not differ 
between the groups. Mean values ± SEM of six animals are represented. 
 
Energy parameters in plasma and skeletal muscle in resting mice and mice after exhaustive 
exercise 
As shown in Table 4, plasma lactate levels increased significantly with exercise in all the 
groups. By trend, lactate concentrations after exercise were lower in the three 
supplemented groups as compared to the control group, though not reaching statistical 
significance. Creatine kinase activity was not different between supplemented and control 
animals and showed a slight elevation with exercise compared to resting conditions (results 
not shown). 
Energy parameters were determined in separate samples of white and red quadriceps 
femoris (Table 4). The creatine and phosphocreatine concentrations were not different 
between supplemented and control groups and were not significantly influenced by 
exercise. Similarly, the skeletal muscle ATP content was not affected by exercise. There 
were no significant differences between control and supplemented groups, although there 
was a trend for a higher ATP content in red fibers from supplemented mice. The glycogen 
content was higher in white skeletal muscle fibers compared to red fibers. After exercise, a 
significant decrease of the glycogen content was observed in white fibers, while no 
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difference was noticed in red fibers. The glycogen content after exercise was by trend 
higher in treated groups, but again without reaching statistical difference. 
 
 CTRL CN ACN PCN CTRL CN ACN PCN 
 Red quadriceps 
 Resting conditions Exhaustive exercise 
Creatine 
(mol/kg w.w.)  
25.4±1.5 23.6±1.3 28.2±0.8 25.2±2.1 25.8±1.2 26.6±1.3 24.8±1.8 28.3±1.4 
Phosphocreatine 
(mol/kg w.w.) 
3.1±1.2 7.5±1.8 7.1±1.0 6.1±1.8 4.4±1.1 7.7±1.8 5.5±1.4 7.0±1.2 
ATP 
(mol/kg w.w.) 
4.3±0.6 8.6±1.7 9.9±0.9 8.5±1.4 6.6±1.2 11.0±1.6 8.8±1.0 9.3±1.2 
Glycogen 
(mmol/kg w.w.) 
9.5±1.2 11.8±1.0 12.8±1.0 11.5±2.9 7.3±1.7 14.7±2.3 11.1±0.8 8.5±1.9 
 White quadriceps 
 Resting conditions Exhaustive exercise 
Creatine 
(mol/kg w.w.)  
23.7±2.5 21.8±2.5 21.8±2.3 21.6±1.5 26.1±2.0 26.1±1.4 23.0±2.1 24.5±1.2 
Phosphocreatine 
(mol/kg w.w.) 
11.8±2.0 12.1±0.4 10.9±2.5 10.3±2.0 8.1±1.3 7.7±2.2 12.1±0.9 9.3±1.3 
ATP 
(mol/kg w.w.) 
8.2±1.0 9.7±1.0 9.6±0.6 9.2±0.9 9.4±1.0 9.1±2.0 10.9±1.1 9.3±0.7 
Glycogen 
(mmol/kg w.w.) 
17.0±2.9 13.6±1.5 20.9±1.7 15.1±1.4 5.6±2.0* 9.7±1.4 11.3±1.1* 12.6±2.5 
 Plasma 
 Resting conditions Exhaustive exercise 
Lactate 
(mmol/L) 
2.2±0.2 2.2±0.2 2.1±0.2 1.9±0.1 6.2±0.5** 4.8±0.3** 5.0±0.2** 5.2±0.5** 
 
Table 4: Effect of exercise on skeletal muscle and plasma parameters. Mean values ± SEM of six animals are 
represented. **: p<0.01 compared to resting values, * p<0.05 compared to resting values. 
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7.5. Discussion 
In this study we investigated the effects of carnitine, acetylcarnitine, and propionylcarnitine 
on the muscle carnitine balance and on exercise capacity of mice. 
We could show that carnitine, acetylcarnitine or propionylcarnitine supplementation does 
not influence the skeletal muscle carnitine pool when administered orally for 4 weeks at a 
dose of 2 mmol/kg/d. Other animal studies also reported no effect of carnitine 
supplementation on the skeletal muscle carnitine content. In rats, low oral doses of carnitine 
or acetylcarnitine (200 mol/kg/d) for 14 days did not increase the muscle carnitine pool 
(Lambert et al., 2009). In mice, a higher carnitine dose (200 mg/kg/d) for five weeks also 
failed to show an effect on the skeletal muscle carnitine pool (Primassin et al., 2008). The 
few animal studies performed in rats or mice reporting a positive effect of carnitine 
supplementation on the skeletal muscle carnitine pool, either used high parenteral doses 
during a relatively long period of time (4 mmol/kg/d during 8 weeks) (Negrao et al., 1987) or 
determined the carnitine content only in soleus muscle (Bacurau et al., 2003). We could not 
confirm this finding in deep quadriceps biopsies which mainly contained red fibers similar to 
the soleus muscle. 
In humans, most studies failed to show an impact of carnitine supplementation on total 
muscle carnitine content and on performance (Barnett et al., 1994; Wachter et al., 2002). 
Recently, increased carnitine muscle concentrations were reported in muscle of humans 
treated with high amounts of carbohydrates to induce hyperinsulinemia (Wall et al., 2011). It 
was hypothesized that insulin enhances carnitine transport via stimulation of the Na+/K+ 
ATPase, leading to the formation of a higher Na+ gradient to drive the sodium-dependent 
carnitine transporter OCTN2. In a similar study, a higher expression of OCTN2 5 hours after 
an infusion of carnitine and insulin was demonstrated, rendering a second possible 
explanation for the observed increase in the skeletal muscle carnitine content under 
hyperinsulinemic conditions (Stephens et al., 2006). In the study of Wall et al. the increase 
of the skeletal muscle carnitine content was observed only in the group treated for 24 
weeks and not in the group treated for 12 weeks, suggesting that long supplementation 
periods are required to increase the muscle carnitine pool (Wall et al., 2011). 
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It has to be pointed out that the transport mechanisms of carnitine into the muscle are not 
fully characterized. It is established that the sodium-dependent carnitine carrier OCTN2 is 
expressed in skeletal muscle (Nezu et al., 1999; Spaniol et al., 2001; Stephens et al., 2006; 
Tamai et al., 1998; Tamai et al., 2000). On the other hand, the study of Berardi et al. 
(Berardi et al., 2000) using rat skeletal muscle membrane vesicles revealed carnitine 
transport characteristics which are not completely compatible with the function of OCTN2. It 
is therefore currently unclear whether the transport of carnitine into skeletal muscle can fully 
be explained by OCTN2 or whether additional carnitine carriers exist. 
In mice, the bioavailability of low doses of carnitine (250 ng/kg) was reported to be 67% 
(Yokogawa et al., 1999), which is clearly higher than the values found in the current study. 
For acetylcarnitine and propionylcarnitine, the absorption profile in mice is not known. In 
humans, although it was suggested that acetylcarnitine is partly hydrolyzed in enterocytes, 
oral doses of acetylcarnitine increased the corresponding plasma concentrations by 40% 
(Rebouche, 2004). The bioavailability of propionylcarnitine has not been determined in 
mice, but has been estimated to be less than 20% (Mancinelli et al., 2005). Our study was 
not designed as a pharmacokinetic study, but nevertheless allowed to estimate some 
kinetic parameters of the compounds administered. As shown in Table 3, the bioavailability of 
carnitine, acetylcarnitine and propionylcarnitine is in the range of 20 – 23% irrespectively of 
the compound administered and based on urinary excretion of carnitine and oral ingestion. 
The comparison with the study of Yokogawa et al. suggests that carnitine absorption is 
concentration-dependent (Yokogawa et al., 1999). Furthermore, the current study indicates 
that orally ingested acylcarnitines undergo hydrolysis either in the intestinal tract or in the 
liver, since we could not detect increased concentrations of acylcarnitines in the systemic 
circulation. Further studies assessing the effect of acylcarnitines on the skeletal muscle 
carnitine content and physical performance would have to be carried out with parenteral 
administration. 
As mentioned above, the supplemented carnitine, acetylcarnitine or propionylcarnitine were 
excreted mainly as carnitine and to a lesser extent as acetylcarnitine, independently of the 
supplemented carnitine derivative. Whereas propionylcarnitine was below detection limits in 
urine of control mice, it was present in the urine of all treated animals, also of the mice 
supplemented with carnitine and acetylcarnitine. Similarly, in humans treated with oral 
carnitine, elevated acetylcarnitine and propionylcarnitine were observed in plasma and 
urine (Cao et al., 2009). Furthermore, in patients with end-stage renal failure undergoing 
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hemodialysis, intravenous administration of carnitine was associated with increased plasma 
concentrations of acylcarnitines and increased elimination of acylcarnitines by dialysis 
(Vernez et al., 2006). These findings suggest that the circulating plasma carnitine is 
exchanged with the tissue pool, where it undergoes intensive transacetylation processes. 
After exercise, we did not observe significant differences in the skeletal muscle 
phosphocreatine content compared with resting conditions, suggesting that exercise was 
not intensive enough, even though the mice were exhausted. Although the interval between 
end of exercise and sacrifice of the mice was in no case longer than 15 minutes, this period 
may have been long enough to allow at least partial recovery of the phosphocreatine pool. 
Exhaustive exercise is supported by the observed increase in the plasma lactate 
concentrations in exercising mice and in the decrease of the glycogen content in skeletal 
muscle. 
In conclusion, oral supplementation of carnitine, acetylcarnitine or propionylcarnitine was 
associated with increased plasma concentrations of total carnitine and increased urinary 
excretion of carnitine, but did not affect the skeletal muscle carnitine content. Accordingly, 
physical performance and skeletal muscle energy metabolism were not affected by 
carnitine supplementation.  
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8. CONCLUSION AND OUTLOOK 
Carnitine has been the center of intensive research since its discovery in 1905. After these 
years, the interest about carnitine remains intact. The present work was focused on 
methodological aspects for the determination of carnitine and its derivatives and on 
functional aspects of this substance. 
In the first project, we investigated the effects of valproate on carnitine homeostasis. We 
observed that the carnitine balance can be disturbed by exogenous factors such as 
valproate. In healthy individuals, this disturbance has no implication since the initial 
carnitine loss is compensated by a more effective renal reabsorption. The mechanisms 
leading to this compensation are not fully understood yet. The carnitine body pool is an 
elaborate equilibrium between biosynthesis, enteral absorption and renal reabsorption, as 
illustrated in vegetarians who compensate their low carnitine intake with efficient renal 
reabsorption (Lombard et al., 1989). However, the fact that patients under valproate therapy 
do develop hypocarnitinemia in some cases as reported in the literature (Chung et al., 
1997; Rodriguez-Segade et al., 1989), points out the complexity and subtlety of this 
balance. Many parameters are at stake, like genetic predispositions or concomitant 
pathologies, and the prevention of hypocarnitinemia and its potentially severe 
consequences depends on the comprehension of the involved factors. 
Analytical methods to determine carnitine and its acyl-derivatives were developed parallel 
to the studies about the functions of carnitine. Any research depends on the robustness of 
the methods applied to the production of the data: no method means no data, fragile 
methods mean questionable data. The determination of carnitine and acylcarnitines 
remains a challenging task because of the endogenous nature of the analytes, their broad 
range of polarity and their variable physiological concentrations. We developed a method 
for the simultaneous analysis of carnitine and three of its derivatives, representative of the 
endogenous polarity range. Confronted to matrix effects, we applied the addition method for 
the quantification of the analytes, overcoming at the same time the problem of the ubiquity 
of carnitine and acylcarnitines in biological matrices. 
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The importance of reliable analytical methods is highlighted by their application. Carnitine 
profiling is well established for the new born screening of metabolic diseases such as 
organic acidurias or fatty acid oxidation disorders (Chace et al., 2003). Certain pathologies 
or treatments are as well associated with specific acylcarnitines patterns. For example, a 
biotin deficiency can be detected by the presence of 3-hydroxyvalerylcarnitine in plasma or 
urine of affected subjects (Stratton et al., 2010; Stratton et al., 2011). Another example 
illustrated in the first project of this thesis is the detection of valproylcarnitine in plasma and 
urine samples of patients treated with this substance (Millington et al., 1985). When 
considering these examples, the potential of carnitine profiling could go even beyond its 
actual utilizations. If substances like valproate or pivalate, as mentioned in the introduction, 
are eliminated as carnitine derivatives, it is probable that other substances with similar 
structures or structures convertible to CoA derivatives can be conjugated to carnitine and 
eliminated as such. These specific acylcarnitines are the proof of an exposure to the mother 
substance and their presence could be a valuable tool in toxicological screenings. Specific 
acylcarnitines patterns might as well be revealing of a specific disease, like organic 
acidurias are or another metabolic disease where the carnitine profile has not been 
investigated yet. Sensitive and reliable analytical methods are indispensable to exploit this 
potential. 
The main roles of carnitine in bioenergetics have been recognized last century (Brass et al., 
1980; Childress et al., 1967; Fritz, 1955). Carnitine ensures normal physiological functions 
as carrier of long-chain fatty acids and as regulator of the acetyl-CoA/CoASH ratio. The 
utility of carnitine supplementation to enhance physical activity is controversial. Surely 
carnitine does not harm. With a lethal dose of ~ 8 g/kg for a mouse (Wolff et al., 1971), 
higher than kitchen salt (Boyd et al., 1963), no cases of carnitine intoxication have been 
reported so far. But does it positively influence muscle metabolism, particularly in situations 
where energy metabolism is impaired such as in diabetic or obese patients? Considering 
the fact that ex vivo experiments support a beneficial effect of carnitine (Brass et al., 1993), 
the question seems rather to be how the muscle could incorporate more than it already 
contains. As shown in our in vivo animal project, oral supplementation of short-chain 
acylcarnitines seems not to be the answer to that question. Only low concentrations of 
acetylcarnitine and propionylcarnitine reach the plasma compartment when supplemented 
in drinking water, with no influence on muscle content. By avoiding incomplete 
reabsorption, a parenteral application of these acylcarnitines would enhance the plasma 
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concentrations and the probability of entering the muscle. Other carnitine “prodrugs” or 
modified pharmaceutical applications might also be considered to increase carnitine muscle 
content. 
Another key for the penetration of carnitine into the muscle relies on a better understanding 
of the transport mechanisms of carnitine into the muscle and the regulation of the 
transporters involved. The presence of OCTN2 on the sarcolemmal membrane is 
undeniable but this transporter alone cannot account for all carnitine movements in and out 
of the muscle. This is illustrated by the fact that patients with systemic carnitine deficiency 
can benefit from a carnitine supplementation even though they do not possess a functional 
OCTN2. Multi-component transport systems have been described in cultured muscle cells 
and in muscle vesicles (Berardi et al., 2000; Martinuzzi et al., 1991). Whereas OCTN2 
expression seems to be influenced by insulin circulating concentrations (Stephens et al., 
2006; Wall et al., 2011), the situation regarding other transporters and their regulation is 
vague, leaving the way open for further research. 
 
In conclusion, research about carnitine and its derivatives still has a bright future lying 
ahead. This tiny molecule will keep fascinating through its multiple facets and its invaluable 
involvement in our proper functioning. This thesis wanted to bring a modest contribution to 
the carnitine research, however raising just as many questions, if not more, as it answered. 
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